<?xml version='1.0' encoding='UTF-8'?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1993-04-01" modified="2020-08-12" version="243">
<accession>P29590</accession>
<accession>E9PBR7</accession>
<accession>P29591</accession>
<accession>P29592</accession>
<accession>P29593</accession>
<accession>Q00755</accession>
<accession>Q15959</accession>
<accession>Q59FP9</accession>
<accession>Q8WUA0</accession>
<accession>Q96S41</accession>
<accession>Q9BPW2</accession>
<accession>Q9BWP7</accession>
<accession>Q9BZX6</accession>
<accession>Q9BZX7</accession>
<accession>Q9BZX8</accession>
<accession>Q9BZX9</accession>
<accession>Q9BZY0</accession>
<accession>Q9BZY2</accession>
<accession>Q9BZY3</accession>
<name>PML_HUMAN</name>
<protein>
<recommendedName>
<fullName>Protein PML</fullName>
</recommendedName>
<alternativeName>
<fullName>Promyelocytic leukemia protein</fullName>
</alternativeName>
<alternativeName>
<fullName>RING finger protein 71</fullName>
</alternativeName>
<alternativeName>
<fullName>Tripartite motif-containing protein 19</fullName>
</alternativeName>
</protein>
<gene>
<name type="primary">PML</name>
<name type="synonym">MYL</name>
<name type="synonym">PP8675</name>
<name type="synonym">RNF71</name>
<name type="synonym">TRIM19</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1991" name="Cell" volume="66" first="675" last="684">
<title>The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR.</title>
<authorList>
<person name="de The H."/>
<person name="Lavau C."/>
<person name="Marchio A."/>
<person name="Chomienne C."/>
<person name="Degos L."/>
<person name="Dejean A."/>
</authorList>
<dbReference type="PubMed" id="1652369"/>
<dbReference type="DOI" id="10.1016/0092-8674(91)90113-d"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PML-3)</scope>
<scope>DISEASE</scope>
</reference>
<reference key="2">
<citation type="journal article" date="1991" name="Science" volume="254" first="1371" last="1374">
<title>Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia.</title>
<authorList>
<person name="Goddard A.D."/>
<person name="Borrow J."/>
<person name="Freemont P.S."/>
<person name="Solomon E."/>
</authorList>
<dbReference type="PubMed" id="1720570"/>
<dbReference type="DOI" id="10.1126/science.1720570"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS PML-1; PML-5 AND PML-8)</scope>
<scope>CHROMOSOMAL TRANSLOCATION WITH RARA</scope>
<scope>DISEASE</scope>
<scope>VARIANT LEU-645</scope>
</reference>
<reference key="3">
<citation type="journal article" date="1992" name="EMBO J." volume="11" first="629" last="642">
<title>Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins.</title>
<authorList>
<person name="Kastner P."/>
<person name="Perez A."/>
<person name="Lutz Y."/>
<person name="Rochette-Egly C."/>
<person name="Gaub M.P."/>
<person name="Durand B."/>
<person name="Lanotte M."/>
<person name="Berger R."/>
<person name="Chambon P."/>
</authorList>
<dbReference type="PubMed" id="1311253"/>
<dbReference type="DOI" id="10.1002/j.1460-2075.1992.tb05095.x"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PML-4)</scope>
</reference>
<reference key="4">
<citation type="journal article" date="1991" name="Cell" volume="66" first="663" last="674">
<title>Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML.</title>
<authorList>
<person name="Kakizuka A."/>
<person name="Miller W.H. Jr."/>
<person name="Umenono K."/>
<person name="Warrell R.P. Jr."/>
<person name="Frankel S.R."/>
<person name="Murty V.V."/>
<person name="Dmitrovsky E."/>
<person name="Evans R.M."/>
</authorList>
<dbReference type="PubMed" id="1652368"/>
<dbReference type="DOI" id="10.1016/0092-8674(91)90112-c"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PML-6)</scope>
</reference>
<reference key="5">
<citation type="journal article" date="2001" name="EMBO J." volume="20" first="2140" last="2151">
<title>The tripartite motif family identifies cell compartments.</title>
<authorList>
<person name="Reymond A."/>
<person name="Meroni G."/>
<person name="Fantozzi A."/>
<person name="Merla G."/>
<person name="Cairo S."/>
<person name="Luzi L."/>
<person name="Riganelli D."/>
<person name="Zanaria E."/>
<person name="Messali S."/>
<person name="Cainarca S."/>
<person name="Guffanti A."/>
<person name="Minucci S."/>
<person name="Pelicci P.G."/>
<person name="Ballabio A."/>
</authorList>
<dbReference type="PubMed" id="11331580"/>
<dbReference type="DOI" id="10.1093/emboj/20.9.2140"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS PML-1; PML-2; PML-4; PML-5; PML-6; PML-7; PML-8; PML-12 AND PML-14)</scope>
<scope>VARIANT LEU-645</scope>
</reference>
<reference key="6">
<citation type="submission" date="1992-01" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Goddard A.D."/>
<person name="Solomon E."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PML-6)</scope>
</reference>
<reference key="7">
<citation type="submission" date="2003-08" db="EMBL/GenBank/DDBJ databases">
<title>Cloning of human full-length CDSs in BD Creator(TM) system donor vector.</title>
<authorList>
<person name="Kalnine N."/>
<person name="Chen X."/>
<person name="Rolfs A."/>
<person name="Halleck A."/>
<person name="Hines L."/>
<person name="Eisenstein S."/>
<person name="Koundinya M."/>
<person name="Raphael J."/>
<person name="Moreira D."/>
<person name="Kelley T."/>
<person name="LaBaer J."/>
<person name="Lin Y."/>
<person name="Phelan M."/>
<person name="Farmer A."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM PML-13)</scope>
</reference>
<reference key="8">
<citation type="submission" date="2005-03" db="EMBL/GenBank/DDBJ databases">
<title>Homo sapiens protein coding cDNA.</title>
<authorList>
<person name="Totoki Y."/>
<person name="Toyoda A."/>
<person name="Takeda T."/>
<person name="Sakaki Y."/>
<person name="Tanaka A."/>
<person name="Yokoyama S."/>
<person name="Ohara O."/>
<person name="Nagase T."/>
<person name="Kikuno R.F."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM PML-11)</scope>
<source>
<tissue>Brain</tissue>
</source>
</reference>
<reference key="9">
<citation type="journal article" date="2006" name="Nature" volume="440" first="671" last="675">
<title>Analysis of the DNA sequence and duplication history of human chromosome 15.</title>
<authorList>
<person name="Zody M.C."/>
<person name="Garber M."/>
<person name="Sharpe T."/>
<person name="Young S.K."/>
<person name="Rowen L."/>
<person name="O'Neill K."/>
<person name="Whittaker C.A."/>
<person name="Kamal M."/>
<person name="Chang J.L."/>
<person name="Cuomo C.A."/>
<person name="Dewar K."/>
<person name="FitzGerald M.G."/>
<person name="Kodira C.D."/>
<person name="Madan A."/>
<person name="Qin S."/>
<person name="Yang X."/>
<person name="Abbasi N."/>
<person name="Abouelleil A."/>
<person name="Arachchi H.M."/>
<person name="Baradarani L."/>
<person name="Birditt B."/>
<person name="Bloom S."/>
<person name="Bloom T."/>
<person name="Borowsky M.L."/>
<person name="Burke J."/>
<person name="Butler J."/>
<person name="Cook A."/>
<person name="DeArellano K."/>
<person name="DeCaprio D."/>
<person name="Dorris L. III"/>
<person name="Dors M."/>
<person name="Eichler E.E."/>
<person name="Engels R."/>
<person name="Fahey J."/>
<person name="Fleetwood P."/>
<person name="Friedman C."/>
<person name="Gearin G."/>
<person name="Hall J.L."/>
<person name="Hensley G."/>
<person name="Johnson E."/>
<person name="Jones C."/>
<person name="Kamat A."/>
<person name="Kaur A."/>
<person name="Locke D.P."/>
<person name="Madan A."/>
<person name="Munson G."/>
<person name="Jaffe D.B."/>
<person name="Lui A."/>
<person name="Macdonald P."/>
<person name="Mauceli E."/>
<person name="Naylor J.W."/>
<person name="Nesbitt R."/>
<person name="Nicol R."/>
<person name="O'Leary S.B."/>
<person name="Ratcliffe A."/>
<person name="Rounsley S."/>
<person name="She X."/>
<person name="Sneddon K.M.B."/>
<person name="Stewart S."/>
<person name="Sougnez C."/>
<person name="Stone S.M."/>
<person name="Topham K."/>
<person name="Vincent D."/>
<person name="Wang S."/>
<person name="Zimmer A.R."/>
<person name="Birren B.W."/>
<person name="Hood L."/>
<person name="Lander E.S."/>
<person name="Nusbaum C."/>
</authorList>
<dbReference type="PubMed" id="16572171"/>
<dbReference type="DOI" id="10.1038/nature04601"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="10">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM PML-13)</scope>
<source>
<tissue>Kidney</tissue>
</source>
</reference>
<reference key="11">
<citation type="journal article" date="1992" name="Oncogene" volume="7" first="311" last="316">
<title>Molecular rearrangements of the MYL gene in acute promyelocytic leukemia (APL, M3) define a breakpoint cluster region as well as some molecular variants.</title>
<authorList>
<person name="Tong J.H."/>
<person name="Dong S."/>
<person name="Geng J.P."/>
<person name="Huang W."/>
<person name="Wang Z.Y."/>
<person name="Sun G.L."/>
<person name="Chen S.J."/>
<person name="Chen Z."/>
<person name="Larsen C.-J."/>
<person name="Berger R."/>
</authorList>
<dbReference type="PubMed" id="1312695"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 419-466</scope>
<scope>CHROMOSOMAL TRANSLOCATION WITH RARA</scope>
</reference>
<reference key="12">
<citation type="journal article" date="2003" name="Leuk. Lymphoma" volume="44" first="111" last="115">
<title>Cytogenetics, FISH and RT-PCR analysis of acute promyelocytic leukemia: structure of the fusion point in a case lacking classic t(15;17) translocation.</title>
<authorList>
<person name="Fujita K."/>
<person name="Oba R."/>
<person name="Harada H."/>
<person name="Mori H."/>
<person name="Niikura H."/>
<person name="Isoyama K."/>
<person name="Omine M."/>
</authorList>
<dbReference type="PubMed" id="12691149"/>
<dbReference type="DOI" id="10.1080/1042819021000040305"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 454-503</scope>
<scope>CHROMOSOMAL TRANSLOCATION WITH RARA</scope>
</reference>
<reference key="13">
<citation type="journal article" date="1998" name="J. Biol. Chem." volume="273" first="26675" last="26682">
<title>Identification of three major sentrinization sites in PML.</title>
<authorList>
<person name="Kamitani T."/>
<person name="Kito K."/>
<person name="Nguyen H.P."/>
<person name="Wada H."/>
<person name="Fukuda-Kamitani T."/>
<person name="Yeh E.T.H."/>
</authorList>
<dbReference type="PubMed" id="9756909"/>
<dbReference type="DOI" id="10.1074/jbc.273.41.26675"/>
</citation>
<scope>SUMOYLATION AT LYS-65; LYS-160 AND LYS-490</scope>
<scope>MUTAGENESIS OF LYS-65; LYS-133; LYS-150; LYS-160 AND LYS-490</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>FUNCTION</scope>
</reference>
<reference key="14">
<citation type="journal article" date="1998" name="J. Cell Sci." volume="111" first="1319" last="1329">
<title>Ret finger protein is a normal component of PML nuclear bodies and interacts directly with PML.</title>
<authorList>
<person name="Cao T."/>
<person name="Duprez E."/>
<person name="Borden K.L."/>
<person name="Freemont P.S."/>
<person name="Etkin L.D."/>
</authorList>
<dbReference type="PubMed" id="9570750"/>
</citation>
<scope>INTERACTION WITH TRIM27</scope>
</reference>
<reference key="15">
<citation type="journal article" date="1998" name="J. Virol." volume="72" first="758" last="766">
<title>An arenavirus RING (zinc-binding) protein binds the oncoprotein promyelocyte leukemia protein (PML) and relocates PML nuclear bodies to the cytoplasm.</title>
<authorList>
<person name="Borden K.L."/>
<person name="Campbell-Dwyer E.J."/>
<person name="Salvato M.S."/>
</authorList>
<dbReference type="PubMed" id="9420283"/>
</citation>
<scope>INTERACTION WITH LASSA VIRUS Z PROTEIN (MICROBIAL INFECTION)</scope>
</reference>
<reference key="16">
<citation type="journal article" date="1999" name="Nat. Genet." volume="23" first="287" last="295">
<title>A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins.</title>
<authorList>
<person name="Zhong S."/>
<person name="Delva L."/>
<person name="Rachez C."/>
<person name="Cenciarelli C."/>
<person name="Gandini D."/>
<person name="Zhang H."/>
<person name="Kalantry S."/>
<person name="Freedman L.P."/>
<person name="Pandolfi P.P."/>
</authorList>
<dbReference type="PubMed" id="10610177"/>
<dbReference type="DOI" id="10.1038/15463"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH RARA; RXRA AND TRIM24</scope>
</reference>
<reference key="17">
<citation type="journal article" date="2000" name="Blood" volume="95" first="2748" last="2752">
<title>Role of SUMO-1-modified PML in nuclear body formation.</title>
<authorList>
<person name="Zhong S."/>
<person name="Muller S."/>
<person name="Ronchetti S."/>
<person name="Freemont P.S."/>
<person name="Dejean A."/>
<person name="Pandolfi P.P."/>
</authorList>
<dbReference type="PubMed" id="10779416"/>
</citation>
<scope>SUMOYLATION AT LYS-65; LYS-160 AND LYS-490</scope>
</reference>
<reference key="18">
<citation type="journal article" date="2000" name="J. Exp. Med." volume="191" first="631" last="640">
<title>Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis.</title>
<authorList>
<person name="Zhong S."/>
<person name="Salomoni P."/>
<person name="Ronchetti S."/>
<person name="Guo A."/>
<person name="Ruggero D."/>
<person name="Pandolfi P.P."/>
</authorList>
<dbReference type="PubMed" id="10684855"/>
<dbReference type="DOI" id="10.1084/jem.191.4.631"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH DAXX</scope>
</reference>
<reference key="19">
<citation type="journal article" date="2000" name="Mol. Cell. Biol." volume="20" first="1784" last="1796">
<title>Sequestration and inhibition of Daxx-mediated transcriptional repression by PML.</title>
<authorList>
<person name="Li H."/>
<person name="Leo C."/>
<person name="Zhu J."/>
<person name="Wu X."/>
<person name="O'Neil J."/>
<person name="Park E.-J."/>
<person name="Chen J.D."/>
</authorList>
<dbReference type="PubMed" id="10669754"/>
<dbReference type="DOI" id="10.1128/mcb.20.5.1784-1796.2000"/>
</citation>
<scope>INTERACTION WITH DAXX</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="20">
<citation type="journal article" date="2000" name="Nat. Cell Biol." volume="2" first="730" last="736">
<title>The function of PML in p53-dependent apoptosis.</title>
<authorList>
<person name="Guo A."/>
<person name="Salomoni P."/>
<person name="Luo J."/>
<person name="Shih A."/>
<person name="Zhong S."/>
<person name="Gu W."/>
<person name="Pandolfi P.P."/>
</authorList>
<dbReference type="PubMed" id="11025664"/>
<dbReference type="DOI" id="10.1038/35036365"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH TP53</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="21">
<citation type="journal article" date="2001" name="EMBO J." volume="20" first="3495" last="3505">
<title>PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator.</title>
<authorList>
<person name="Regad T."/>
<person name="Saib A."/>
<person name="Lallemand-Breitenbach V."/>
<person name="Pandolfi P.P."/>
<person name="de The H."/>
<person name="Chelbi-Alix M.K."/>
</authorList>
<dbReference type="PubMed" id="11432836"/>
<dbReference type="DOI" id="10.1093/emboj/20.13.3495"/>
</citation>
<scope>FUNCTION IN HUMAN FOAMY VIRUS RESTRICTION</scope>
<scope>INTERACTION WITH HUMAN FOAMY VIRUS BEL1 AND BET (MICROBIAL INFECTION)</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2001" name="Oncogene" volume="20" first="7223" last="7233">
<title>PML protein isoforms and the RBCC/TRIM motif.</title>
<authorList>
<person name="Jensen K."/>
<person name="Shiels C."/>
<person name="Freemont P.S."/>
</authorList>
<dbReference type="PubMed" id="11704850"/>
<dbReference type="DOI" id="10.1038/sj.onc.1204765"/>
</citation>
<scope>NOMENCLATURE OF ISOFORMS PML-1 THROUGH PML-7</scope>
</reference>
<reference key="23">
<citation type="journal article" date="2002" name="EMBO J." volume="21" first="2383" last="2396">
<title>Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence.</title>
<authorList>
<person name="Langley E."/>
<person name="Pearson M."/>
<person name="Faretta M."/>
<person name="Bauer U.-M."/>
<person name="Frye R.A."/>
<person name="Minucci S."/>
<person name="Pelicci P.G."/>
<person name="Kouzarides T."/>
</authorList>
<dbReference type="PubMed" id="12006491"/>
<dbReference type="DOI" id="10.1093/emboj/21.10.2383"/>
</citation>
<scope>INTERACTION WITH SIRT1</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2002" name="Mol. Cell" volume="10" first="843" last="855">
<title>SUMO-1 protease-1 regulates gene transcription through PML.</title>
<authorList>
<person name="Best J.L."/>
<person name="Ganiatsas S."/>
<person name="Agarwal S."/>
<person name="Changou A."/>
<person name="Salomoni P."/>
<person name="Shirihai O."/>
<person name="Meluh P.B."/>
<person name="Pandolfi P.P."/>
<person name="Zon L.I."/>
</authorList>
<dbReference type="PubMed" id="12419228"/>
<dbReference type="DOI" id="10.1016/s1097-2765(02)00699-8"/>
</citation>
<scope>SUMOYLATION</scope>
<scope>DESUMOYLATION BY SENP2</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2002" name="Nat. Cell Biol." volume="4" first="865" last="870">
<title>PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2.</title>
<authorList>
<person name="Yang S."/>
<person name="Kuo C."/>
<person name="Bisi J.E."/>
<person name="Kim M.K."/>
</authorList>
<dbReference type="PubMed" id="12402044"/>
<dbReference type="DOI" id="10.1038/ncb869"/>
</citation>
<scope>FUNCTION IN DNA REPAIR</scope>
<scope>PHOSPHORYLATION AT SER-117 BY CHEK2</scope>
<scope>INTERACTION WITH CHEK2</scope>
</reference>
<reference key="26">
<citation type="journal article" date="2002" name="Oncogene" volume="21" first="7957" last="7970">
<title>Rabies virus P and small P products interact directly with PML and reorganize PML nuclear bodies.</title>
<authorList>
<person name="Blondel D."/>
<person name="Regad T."/>
<person name="Poisson N."/>
<person name="Pavie B."/>
<person name="Harper F."/>
<person name="Pandolfi P.P."/>
<person name="De The H."/>
<person name="Chelbi-Alix M.K."/>
</authorList>
<dbReference type="PubMed" id="12439746"/>
<dbReference type="DOI" id="10.1038/sj.onc.1205931"/>
</citation>
<scope>INTERACTION WITH RABIES VIRUS PHOSPHOPROTEINS</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>FUNCTION</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2003" name="J. Biol. Chem." volume="278" first="33134" last="33141">
<title>The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation.</title>
<authorList>
<person name="Louria-Hayon I."/>
<person name="Grossman T."/>
<person name="Sionov R.V."/>
<person name="Alsheich O."/>
<person name="Pandolfi P.P."/>
<person name="Haupt Y."/>
</authorList>
<dbReference type="PubMed" id="12810724"/>
<dbReference type="DOI" id="10.1074/jbc.m301264200"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH CHEK2 AND TP53</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2003" name="Mol. Cell. Biol." volume="23" first="4247" last="4256">
<title>PML colocalizes with and stabilizes the DNA damage response protein TopBP1.</title>
<authorList>
<person name="Xu Z.-X."/>
<person name="Timanova-Atanasova A."/>
<person name="Zhao R.-X."/>
<person name="Chang K.-S."/>
</authorList>
<dbReference type="PubMed" id="12773567"/>
<dbReference type="DOI" id="10.1128/mcb.23.12.4247-4256.2003"/>
</citation>
<scope>INTERACTION WITH TOPBP1</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2004" name="J. Biol. Chem." volume="279" first="5374" last="5379">
<title>The coiled-coil domain is the structural determinant for mammalian homologues of Drosophila Sina-mediated degradation of promyelocytic leukemia protein and other tripartite motif proteins by the proteasome.</title>
<authorList>
<person name="Fanelli M."/>
<person name="Fantozzi A."/>
<person name="De Luca P."/>
<person name="Caprodossi S."/>
<person name="Matsuzawa S."/>
<person name="Lazar M.A."/>
<person name="Pelicci P.G."/>
<person name="Minucci S."/>
</authorList>
<dbReference type="PubMed" id="14645235"/>
<dbReference type="DOI" id="10.1074/jbc.m306407200"/>
</citation>
<scope>INTERACTION WITH SIAH1</scope>
<scope>DEGRADATION</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2004" name="J. Biol. Chem." volume="279" first="19091" last="19098">
<title>Myeloid Elf-1-like factor, an ETS transcription factor, up-regulates lysozyme transcription in epithelial cells through interaction with promyelocytic leukemia protein.</title>
<authorList>
<person name="Suico M.A."/>
<person name="Yoshida H."/>
<person name="Seki Y."/>
<person name="Uchikawa T."/>
<person name="Lu Z."/>
<person name="Shuto T."/>
<person name="Matsuzaki K."/>
<person name="Nakao M."/>
<person name="Li J.-D."/>
<person name="Kai H."/>
</authorList>
<dbReference type="PubMed" id="14976184"/>
<dbReference type="DOI" id="10.1074/jbc.m312439200"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH ELF4</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2004" name="J. Mol. Biol." volume="339" first="313" last="325">
<title>The Ankrd2 protein, a link between the sarcomere and the nucleus in skeletal muscle.</title>
<authorList>
<person name="Kojic S."/>
<person name="Medeot E."/>
<person name="Guccione E."/>
<person name="Krmac H."/>
<person name="Zara I."/>
<person name="Martinelli V."/>
<person name="Valle G."/>
<person name="Faulkner G."/>
</authorList>
<dbReference type="PubMed" id="15136035"/>
<dbReference type="DOI" id="10.1016/j.jmb.2004.03.071"/>
</citation>
<scope>INTERACTION WITH ANKRD2</scope>
</reference>
<reference key="32">
<citation type="journal article" date="2004" name="Nat. Cell Biol." volume="6" first="665" last="672">
<title>PML regulates p53 stability by sequestering Mdm2 to the nucleolus.</title>
<authorList>
<person name="Bernardi R."/>
<person name="Scaglioni P.P."/>
<person name="Bergmann S."/>
<person name="Horn H.F."/>
<person name="Vousden K.H."/>
<person name="Pandolfi P.P."/>
</authorList>
<dbReference type="PubMed" id="15195100"/>
<dbReference type="DOI" id="10.1038/ncb1147"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH MDM2 AND RPL11</scope>
<scope>PHOSPHORYLATION BY ATR IN RESPONSE TO DNA DAMAGE</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="33">
<citation type="journal article" date="2004" name="Nat. Struct. Mol. Biol." volume="11" first="1114" last="1121">
<title>PML bodies control the nuclear dynamics and function of the CHFR mitotic checkpoint protein.</title>
<authorList>
<person name="Daniels M.J."/>
<person name="Marson A."/>
<person name="Venkitaraman A.R."/>
</authorList>
<dbReference type="PubMed" id="15467728"/>
<dbReference type="DOI" id="10.1038/nsmb837"/>
</citation>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH CHFR</scope>
</reference>
<reference key="34">
<citation type="journal article" date="2004" name="Nature" volume="431" first="205" last="211">
<title>Cytoplasmic PML function in TGF-beta signalling.</title>
<authorList>
<person name="Lin H.K."/>
<person name="Bergmann S."/>
<person name="Pandolfi P.P."/>
</authorList>
<dbReference type="PubMed" id="15356634"/>
<dbReference type="DOI" id="10.1038/nature02783"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH TGFBR1; TGFBR2; SMAD2; SMAD3 AND ZFYVE9/SARA</scope>
</reference>
<reference key="35">
<citation type="journal article" date="2005" name="Biochem. Biophys. Res. Commun." volume="330" first="746" last="754">
<title>Requirement of the coiled-coil domain of PML-RARalpha oncoprotein for localization, sumoylation, and inhibition of monocyte differentiation.</title>
<authorList>
<person name="Kim Y.E."/>
<person name="Kim D.Y."/>
<person name="Lee J.M."/>
<person name="Kim S.T."/>
<person name="Han T.H."/>
<person name="Ahn J.H."/>
</authorList>
<dbReference type="PubMed" id="15809060"/>
<dbReference type="DOI" id="10.1016/j.bbrc.2005.03.052"/>
</citation>
<scope>INTERACTION OF PML-RARALPHA ONCOPROTEIN WITH UBE2I</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>SUMOYLATION</scope>
<scope>MUTAGENESIS OF CYS-88 AND PRO-89</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2006" name="Cancer Res." volume="66" first="6192" last="6198">
<title>Characterization of endogenous human promyelocytic leukemia isoforms.</title>
<authorList>
<person name="Condemine W."/>
<person name="Takahashi Y."/>
<person name="Zhu J."/>
<person name="Puvion-Dutilleul F."/>
<person name="Guegan S."/>
<person name="Janin A."/>
<person name="de The H."/>
</authorList>
<dbReference type="PubMed" id="16778193"/>
<dbReference type="DOI" id="10.1158/0008-5472.can-05-3792"/>
</citation>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="37">
<citation type="journal article" date="2006" name="Cell" volume="127" first="635" last="648">
<title>Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.</title>
<authorList>
<person name="Olsen J.V."/>
<person name="Blagoev B."/>
<person name="Gnad F."/>
<person name="Macek B."/>
<person name="Kumar C."/>
<person name="Mortensen P."/>
<person name="Mann M."/>
</authorList>
<dbReference type="PubMed" id="17081983"/>
<dbReference type="DOI" id="10.1016/j.cell.2006.09.026"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-403; SER-518; SER-527 AND SER-530</scope>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-565 (ISOFORM PML-5)</scope>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-518; SER-527 AND SER-530 (ISOFORM PML-6)</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="38">
<citation type="journal article" date="2006" name="J. Cell Biol." volume="175" first="55" last="66">
<title>Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR.</title>
<authorList>
<person name="Dellaire G."/>
<person name="Ching R.W."/>
<person name="Ahmed K."/>
<person name="Jalali F."/>
<person name="Tse K.C."/>
<person name="Bristow R.G."/>
<person name="Bazett-Jones D.P."/>
</authorList>
<dbReference type="PubMed" id="17030982"/>
<dbReference type="DOI" id="10.1083/jcb.200604009"/>
</citation>
<scope>FUNCTION</scope>
</reference>
<reference key="39">
<citation type="journal article" date="2006" name="J. Virol." volume="80" first="8582" last="8592">
<title>Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense.</title>
<authorList>
<person name="Pampin M."/>
<person name="Simonin Y."/>
<person name="Blondel B."/>
<person name="Percherancier Y."/>
<person name="Chelbi-Alix M.K."/>
</authorList>
<dbReference type="PubMed" id="16912307"/>
<dbReference type="DOI" id="10.1128/jvi.00031-06"/>
</citation>
<scope>FUNCTION IN POLIOVIRUS RESTRICTION</scope>
</reference>
<reference key="40">
<citation type="journal article" date="2006" name="Mol. Cell" volume="24" first="331" last="339">
<title>The mechanisms of PML-nuclear body formation.</title>
<authorList>
<person name="Shen T.H."/>
<person name="Lin H.K."/>
<person name="Scaglioni P.P."/>
<person name="Yung T.M."/>
<person name="Pandolfi P.P."/>
</authorList>
<dbReference type="PubMed" id="17081985"/>
<dbReference type="DOI" id="10.1016/j.molcel.2006.09.013"/>
</citation>
<scope>SUBUNIT</scope>
<scope>SUMOYLATION</scope>
<scope>SUMO-BINDING MOTIF</scope>
<scope>MUTAGENESIS OF CYS-57 AND CYS-60</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="41">
<citation type="journal article" date="2008" name="Genes Cells" volume="13" first="245" last="254">
<title>Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein.</title>
<authorList>
<person name="Shimada N."/>
<person name="Shinagawa T."/>
<person name="Ishii S."/>
</authorList>
<dbReference type="PubMed" id="18298799"/>
<dbReference type="DOI" id="10.1111/j.1365-2443.2008.01165.x"/>
</citation>
<scope>INTERACTION WITH PKM</scope>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>DOMAIN</scope>
<scope>MUTAGENESIS OF LYS-487 AND LYS-490</scope>
</reference>
<reference key="42">
<citation type="journal article" date="2008" name="J. Biol. Chem." volume="283" first="24420" last="24425">
<title>Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis.</title>
<authorList>
<person name="Hayakawa F."/>
<person name="Abe A."/>
<person name="Kitabayashi I."/>
<person name="Pandolfi P.P."/>
<person name="Naoe T."/>
</authorList>
<dbReference type="PubMed" id="18621739"/>
<dbReference type="DOI" id="10.1074/jbc.m802217200"/>
</citation>
<scope>ACETYLATION AT LYS-487 AND LYS-515</scope>
<scope>MUTAGENESIS OF LYS-487 AND LYS-515</scope>
</reference>
<reference key="43">
<citation type="journal article" date="2008" name="J. Virol." volume="82" first="126" last="137">
<title>Nuclear domain 10 components promyelocytic leukemia protein and hDaxx independently contribute to an intrinsic antiviral defense against human cytomegalovirus infection.</title>
<authorList>
<person name="Tavalai N."/>
<person name="Papior P."/>
<person name="Rechter S."/>
<person name="Stamminger T."/>
</authorList>
<dbReference type="PubMed" id="17942542"/>
<dbReference type="DOI" id="10.1128/jvi.01685-07"/>
</citation>
<scope>FUNCTION IN HCMV RESTRICTION</scope>
</reference>
<reference key="44">
<citation type="journal article" date="2008" name="Nature" volume="455" first="813" last="817">
<title>The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network.</title>
<authorList>
<person name="Song M.S."/>
<person name="Salmena L."/>
<person name="Carracedo A."/>
<person name="Egia A."/>
<person name="Lo-Coco F."/>
<person name="Teruya-Feldstein J."/>
<person name="Pandolfi P.P."/>
</authorList>
<dbReference type="PubMed" id="18716620"/>
<dbReference type="DOI" id="10.1038/nature07290"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="45">
<citation type="journal article" date="2008" name="Nat. Cell Biol." volume="10" first="538" last="546">
<title>RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.</title>
<authorList>
<person name="Tatham M.H."/>
<person name="Geoffroy M.C."/>
<person name="Shen L."/>
<person name="Plechanovova A."/>
<person name="Hattersley N."/>
<person name="Jaffray E.G."/>
<person name="Palvimo J.J."/>
<person name="Hay R.T."/>
</authorList>
<dbReference type="PubMed" id="18408734"/>
<dbReference type="DOI" id="10.1038/ncb1716"/>
</citation>
<scope>POLYUBIQUITINATION AT LYS-380; LYS-400; LYS-401 AND LYS-476 BY RNF4</scope>
<scope>PROTEASOMAL DEGRADATION</scope>
<scope>SUMOYLATION</scope>
</reference>
<reference key="46">
<citation type="journal article" date="2007" name="Nat. Cell Biol." volume="9" first="45" last="56">
<title>Functional interaction between PML and SATB1 regulates chromatin-loop architecture and transcription of the MHC class I locus.</title>
<authorList>
<person name="Kumar P.P."/>
<person name="Bischof O."/>
<person name="Purbey P.K."/>
<person name="Notani D."/>
<person name="Urlaub H."/>
<person name="Dejean A."/>
<person name="Galande S."/>
</authorList>
<dbReference type="PubMed" id="17173041"/>
<dbReference type="DOI" id="10.1038/ncb1516"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH SATB1</scope>
</reference>
<reference key="47">
<citation type="journal article" date="2008" name="PLoS ONE" volume="3" first="E2277" last="E2277">
<title>A role for cytoplasmic PML in cellular resistance to viral infection.</title>
<authorList>
<person name="McNally B.A."/>
<person name="Trgovcich J."/>
<person name="Maul G.G."/>
<person name="Liu Y."/>
<person name="Zheng P."/>
</authorList>
<dbReference type="PubMed" id="18509536"/>
<dbReference type="DOI" id="10.1371/journal.pone.0002277"/>
</citation>
<scope>FUNCTION IN HHV-1 RESTRICTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="48">
<citation type="journal article" date="2008" name="Proc. Natl. Acad. Sci. U.S.A." volume="105" first="10762" last="10767">
<title>A quantitative atlas of mitotic phosphorylation.</title>
<authorList>
<person name="Dephoure N."/>
<person name="Zhou C."/>
<person name="Villen J."/>
<person name="Beausoleil S.A."/>
<person name="Bakalarski C.E."/>
<person name="Elledge S.J."/>
<person name="Gygi S.P."/>
</authorList>
<dbReference type="PubMed" id="18669648"/>
<dbReference type="DOI" id="10.1073/pnas.0805139105"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-403; SER-518; SER-527 AND SER-530</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="49">
<citation type="journal article" date="2009" name="Biochem. Biophys. Res. Commun." volume="389" first="84" last="89">
<title>Differential suppressive effect of promyelocytic leukemia protein on the replication of different subtypes/strains of influenza A virus.</title>
<authorList>
<person name="Li W."/>
<person name="Wang G."/>
<person name="Zhang H."/>
<person name="Zhang D."/>
<person name="Zeng J."/>
<person name="Chen X."/>
<person name="Xu Y."/>
<person name="Li K."/>
</authorList>
<dbReference type="PubMed" id="19703418"/>
<dbReference type="DOI" id="10.1016/j.bbrc.2009.08.091"/>
</citation>
<scope>FUNCTION IN INFLUENZA A VIRUS RESTRICTION</scope>
</reference>
<reference key="50">
<citation type="journal article" date="2009" name="J. Cell Sci." volume="122" first="2613" last="2622">
<title>PML-IV functions as a negative regulator of telomerase by interacting with TERT.</title>
<authorList>
<person name="Oh W."/>
<person name="Ghim J."/>
<person name="Lee E.W."/>
<person name="Yang M.R."/>
<person name="Kim E.T."/>
<person name="Ahn J.H."/>
<person name="Song J."/>
</authorList>
<dbReference type="PubMed" id="19567472"/>
<dbReference type="DOI" id="10.1242/jcs.048066"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH TERT</scope>
</reference>
<reference key="51">
<citation type="journal article" date="2009" name="Oncogene" volume="28" first="698" last="708">
<title>PML tumor suppressor is regulated by HIPK2-mediated phosphorylation in response to DNA damage.</title>
<authorList>
<person name="Gresko E."/>
<person name="Ritterhoff S."/>
<person name="Sevilla-Perez J."/>
<person name="Roscic A."/>
<person name="Froebius K."/>
<person name="Kotevic I."/>
<person name="Vichalkovski A."/>
<person name="Hess D."/>
<person name="Hemmings B.A."/>
<person name="Schmitz M.L."/>
</authorList>
<dbReference type="PubMed" id="19015637"/>
<dbReference type="DOI" id="10.1038/onc.2008.420"/>
</citation>
<scope>PHOSPHORYLATION AT SER-8 AND SER-38 BY HIPK2</scope>
<scope>INTERACTION WITH HIPK2</scope>
</reference>
<reference key="52">
<citation type="journal article" date="2009" name="Sci. Signal." volume="2" first="RA46" last="RA46">
<title>Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.</title>
<authorList>
<person name="Mayya V."/>
<person name="Lundgren D.H."/>
<person name="Hwang S.-I."/>
<person name="Rezaul K."/>
<person name="Wu L."/>
<person name="Eng J.K."/>
<person name="Rodionov V."/>
<person name="Han D.K."/>
</authorList>
<dbReference type="PubMed" id="19690332"/>
<dbReference type="DOI" id="10.1126/scisignal.2000007"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-530</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Leukemic T-cell</tissue>
</source>
</reference>
<reference key="53">
<citation type="journal article" date="2010" name="J. Cell Sci." volume="123" first="2014" last="2024">
<title>Two-step colocalization of MORC3 with PML nuclear bodies.</title>
<authorList>
<person name="Mimura Y."/>
<person name="Takahashi K."/>
<person name="Kawata K."/>
<person name="Akazawa T."/>
<person name="Inoue N."/>
</authorList>
<dbReference type="PubMed" id="20501696"/>
<dbReference type="DOI" id="10.1242/jcs.063586"/>
</citation>
<scope>INTERACTION WITH MORC3</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="54">
<citation type="journal article" date="2010" name="J. Virol." volume="84" first="10719" last="10726">
<title>Resistance to rabies virus infection conferred by the PMLIV isoform.</title>
<authorList>
<person name="Blondel D."/>
<person name="Kheddache S."/>
<person name="Lahaye X."/>
<person name="Dianoux L."/>
<person name="Chelbi-Alix M.K."/>
</authorList>
<dbReference type="PubMed" id="20702643"/>
<dbReference type="DOI" id="10.1128/jvi.01286-10"/>
</citation>
<scope>FUNCTION IN RABIES VIRUS RESTRICTION</scope>
</reference>
<reference key="55">
<citation type="journal article" date="2010" name="Oncogene" volume="29" first="5511" last="5522">
<title>SUMO modification of E1B-55K oncoprotein regulates isoform-specific binding to the tumour suppressor protein PML.</title>
<authorList>
<person name="Wimmer P."/>
<person name="Schreiner S."/>
<person name="Everett R.D."/>
<person name="Sirma H."/>
<person name="Groitl P."/>
<person name="Dobner T."/>
</authorList>
<dbReference type="PubMed" id="20639899"/>
<dbReference type="DOI" id="10.1038/onc.2010.284"/>
</citation>
<scope>INTERACTION OF PML-4 AND PML-5 WITH HADV5 E1B-55K (MICROBIAL INFECTION)</scope>
</reference>
<reference key="56">
<citation type="journal article" date="2010" name="Mol. Biol. Cell" volume="21" first="4227" last="4239">
<title>Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies.</title>
<authorList>
<person name="Geoffroy M.C."/>
<person name="Jaffray E.G."/>
<person name="Walker K.J."/>
<person name="Hay R.T."/>
</authorList>
<dbReference type="PubMed" id="20943951"/>
<dbReference type="DOI" id="10.1091/mbc.e10-05-0449"/>
</citation>
<scope>SUMOYLATION</scope>
<scope>UBIQUITINATION</scope>
</reference>
<reference key="57">
<citation type="journal article" date="2010" name="PLoS ONE" volume="5" first="E11418" last="E11418">
<title>Functional polymorphism of the CK2alpha intronless gene plays oncogenic roles in lung cancer.</title>
<authorList>
<person name="Hung M.S."/>
<person name="Lin Y.C."/>
<person name="Mao J.H."/>
<person name="Kim I.J."/>
<person name="Xu Z."/>
<person name="Yang C.T."/>
<person name="Jablons D.M."/>
<person name="You L."/>
</authorList>
<dbReference type="PubMed" id="20625391"/>
<dbReference type="DOI" id="10.1371/journal.pone.0011418"/>
</citation>
<scope>INTERACTION WITH CSNK2A1 AND CSNK2A3</scope>
</reference>
<reference key="58">
<citation type="journal article" date="2010" name="Sci. Signal." volume="3" first="RA3" last="RA3">
<title>Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.</title>
<authorList>
<person name="Olsen J.V."/>
<person name="Vermeulen M."/>
<person name="Santamaria A."/>
<person name="Kumar C."/>
<person name="Miller M.L."/>
<person name="Jensen L.J."/>
<person name="Gnad F."/>
<person name="Cox J."/>
<person name="Jensen T.S."/>
<person name="Nigg E.A."/>
<person name="Brunak S."/>
<person name="Mann M."/>
</authorList>
<dbReference type="PubMed" id="20068231"/>
<dbReference type="DOI" id="10.1126/scisignal.2000475"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-518 AND SER-527</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="59">
<citation type="journal article" date="2010" name="Science" volume="328" first="240" last="243">
<title>Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.</title>
<authorList>
<person name="Zhang X.W."/>
<person name="Yan X.J."/>
<person name="Zhou Z.R."/>
<person name="Yang F.F."/>
<person name="Wu Z.Y."/>
<person name="Sun H.B."/>
<person name="Liang W.X."/>
<person name="Song A.X."/>
<person name="Lallemand-Breitenbach V."/>
<person name="Jeanne M."/>
<person name="Zhang Q.Y."/>
<person name="Yang H.Y."/>
<person name="Huang Q.H."/>
<person name="Zhou G.B."/>
<person name="Tong J.H."/>
<person name="Zhang Y."/>
<person name="Wu J.H."/>
<person name="Hu H.Y."/>
<person name="de The H."/>
<person name="Chen S.J."/>
<person name="Chen Z."/>
</authorList>
<dbReference type="PubMed" id="20378816"/>
<dbReference type="DOI" id="10.1126/science.1183424"/>
</citation>
<scope>INTERACTION WITH UBC9</scope>
<scope>SUBUNIT</scope>
<scope>UBIQUITINATION</scope>
<scope>SUMOYLATION</scope>
<scope>ARSENIC BINDING</scope>
<scope>DOMAIN</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY</scope>
</reference>
<reference key="60">
<citation type="journal article" date="2011" name="BMC Syst. Biol." volume="5" first="17" last="17">
<title>Initial characterization of the human central proteome.</title>
<authorList>
<person name="Burkard T.R."/>
<person name="Planyavsky M."/>
<person name="Kaupe I."/>
<person name="Breitwieser F.P."/>
<person name="Buerckstuemmer T."/>
<person name="Bennett K.L."/>
<person name="Superti-Furga G."/>
<person name="Colinge J."/>
</authorList>
<dbReference type="PubMed" id="21269460"/>
<dbReference type="DOI" id="10.1186/1752-0509-5-17"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="61">
<citation type="journal article" date="2011" name="Biochemistry (Mosc.)" volume="76" first="550" last="554">
<title>Promyelocytic leukemia protein interacts with werner syndrome helicase and regulates double-strand break repair in gamma-irradiation-induced DNA damage responses.</title>
<authorList>
<person name="Liu J."/>
<person name="Song Y."/>
<person name="Qian J."/>
<person name="Liu B."/>
<person name="Dong Y."/>
<person name="Tian B."/>
<person name="Sun Z."/>
</authorList>
<dbReference type="PubMed" id="21639834"/>
<dbReference type="DOI" id="10.1134/s000629791105004x"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH WRN</scope>
</reference>
<reference key="62">
<citation type="journal article" date="2011" name="Cancer Cell" volume="20" first="214" last="228">
<title>A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression.</title>
<authorList>
<person name="Yuan W.C."/>
<person name="Lee Y.R."/>
<person name="Huang S.F."/>
<person name="Lin Y.M."/>
<person name="Chen T.Y."/>
<person name="Chung H.C."/>
<person name="Tsai C.H."/>
<person name="Chen H.Y."/>
<person name="Chiang C.T."/>
<person name="Lai C.K."/>
<person name="Lu L.T."/>
<person name="Chen C.H."/>
<person name="Gu D.L."/>
<person name="Pu Y.S."/>
<person name="Jou Y.S."/>
<person name="Lu K.P."/>
<person name="Hsiao P.W."/>
<person name="Shih H.M."/>
<person name="Chen R.H."/>
</authorList>
<dbReference type="PubMed" id="21840486"/>
<dbReference type="DOI" id="10.1016/j.ccr.2011.07.008"/>
</citation>
<scope>UBIQUITINATION</scope>
<scope>PHOSPHORYLATION AT SER-518</scope>
<scope>MUTAGENESIS OF SER-518</scope>
</reference>
<reference key="63">
<citation type="journal article" date="2011" name="Cell Death Differ." volume="18" first="1450" last="1456">
<title>The role of PML in the control of apoptotic cell fate: a new key player at ER-mitochondria sites.</title>
<authorList>
<person name="Pinton P."/>
<person name="Giorgi C."/>
<person name="Pandolfi P.P."/>
</authorList>
<dbReference type="PubMed" id="21475307"/>
<dbReference type="DOI" id="10.1038/cdd.2011.31"/>
</citation>
<scope>REVIEW ON FUNCTION</scope>
</reference>
<reference key="64">
<citation type="journal article" date="2011" name="Curr. Opin. Cell Biol." volume="23" first="360" last="366">
<title>The nuclear bodies inside out: PML conquers the cytoplasm.</title>
<authorList>
<person name="Carracedo A."/>
<person name="Ito K."/>
<person name="Pandolfi P.P."/>
</authorList>
<dbReference type="PubMed" id="21501958"/>
<dbReference type="DOI" id="10.1016/j.ceb.2011.03.011"/>
</citation>
<scope>REVIEW ON FUNCTION</scope>
</reference>
<reference key="65">
<citation type="journal article" date="2011" name="J. Biol. Chem." volume="286" first="44403" last="44411">
<title>Mitogen-activated protein kinase extracellular signal-regulated kinase 2 phosphorylates and promotes Pin1 protein-dependent promyelocytic leukemia protein turnover.</title>
<authorList>
<person name="Lim J.H."/>
<person name="Liu Y."/>
<person name="Reineke E."/>
<person name="Kao H.Y."/>
</authorList>
<dbReference type="PubMed" id="22033920"/>
<dbReference type="DOI" id="10.1074/jbc.m111.289512"/>
</citation>
<scope>PHOSPHORYLATION AT SER-403; SER-505; SER-518 AND SER-527</scope>
<scope>INTERACTION WITH PIN1 AND MAPK1</scope>
</reference>
<reference key="66">
<citation type="journal article" date="2011" name="J. Cell Sci." volume="124" first="280" last="291">
<title>PML isoforms I and II participate in PML-dependent restriction of HSV-1 replication.</title>
<authorList>
<person name="Cuchet D."/>
<person name="Sykes A."/>
<person name="Nicolas A."/>
<person name="Orr A."/>
<person name="Murray J."/>
<person name="Sirma H."/>
<person name="Heeren J."/>
<person name="Bartelt A."/>
<person name="Everett R.D."/>
</authorList>
<dbReference type="PubMed" id="21172801"/>
<dbReference type="DOI" id="10.1242/jcs.075390"/>
</citation>
<scope>FUNCTION</scope>
</reference>
<reference key="67">
<citation type="journal article" date="2011" name="J. Interferon Cytokine Res." volume="31" first="145" last="158">
<title>Role of promyelocytic leukemia protein in host antiviral defense.</title>
<authorList>
<person name="Geoffroy M.C."/>
<person name="Chelbi-Alix M.K."/>
</authorList>
<dbReference type="PubMed" id="21198351"/>
<dbReference type="DOI" id="10.1089/jir.2010.0111"/>
</citation>
<scope>REVIEW ON FUNCTION IN ANTIVIRAL DEFENSE</scope>
</reference>
<reference key="68">
<citation type="journal article" date="2011" name="J. Virol." volume="85" first="13164" last="13173">
<title>Promyelocytic leukemia isoform IV confers resistance to encephalomyocarditis virus via the sequestration of 3D polymerase in nuclear bodies.</title>
<authorList>
<person name="Maroui M.A."/>
<person name="Pampin M."/>
<person name="Chelbi-Alix M.K."/>
</authorList>
<dbReference type="PubMed" id="21994459"/>
<dbReference type="DOI" id="10.1128/jvi.05808-11"/>
</citation>
<scope>FUNCTION IN EMCV RESTRICTION</scope>
<scope>INTERACTION WITH EMCV P3D-POL (MICROBIAL INFECTION)</scope>
</reference>
<reference key="69">
<citation type="journal article" date="2011" name="Mol. Biol. Cell" volume="22" first="78" last="90">
<title>The SUMO protease SENP6 is a direct regulator of PML nuclear bodies.</title>
<authorList>
<person name="Hattersley N."/>
<person name="Shen L."/>
<person name="Jaffray E.G."/>
<person name="Hay R.T."/>
</authorList>
<dbReference type="PubMed" id="21148299"/>
<dbReference type="DOI" id="10.1091/mbc.e10-06-0504"/>
</citation>
<scope>SUMOYLATION</scope>
<scope>DESUMOYLATION BY SENP6</scope>
</reference>
<reference key="70">
<citation type="journal article" date="2011" name="Mol. Neurobiol." volume="43" first="114" last="123">
<title>The role of PML in the nervous system.</title>
<authorList>
<person name="Salomoni P."/>
<person name="Betts-Henderson J."/>
</authorList>
<dbReference type="PubMed" id="21161613"/>
<dbReference type="DOI" id="10.1007/s12035-010-8156-y"/>
</citation>
<scope>REVIEW ON FUNCTION</scope>
</reference>
<reference key="71">
<citation type="journal article" date="2011" name="PLoS Pathog." volume="7" first="E1001266" last="E1001266">
<title>Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against Varicella-Zoster virus.</title>
<authorList>
<person name="Reichelt M."/>
<person name="Wang L."/>
<person name="Sommer M."/>
<person name="Perrino J."/>
<person name="Nour A.M."/>
<person name="Sen N."/>
<person name="Baiker A."/>
<person name="Zerboni L."/>
<person name="Arvin A.M."/>
</authorList>
<dbReference type="PubMed" id="21304940"/>
<dbReference type="DOI" id="10.1371/journal.ppat.1001266"/>
</citation>
<scope>FUNCTION IN VARICELLA ZOSTER RESTRICTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH VZV VP26 (MICROBIAL INFECTION)</scope>
</reference>
<reference key="72">
<citation type="journal article" date="2011" name="Sci. Signal." volume="4" first="RS3" last="RS3">
<title>System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.</title>
<authorList>
<person name="Rigbolt K.T."/>
<person name="Prokhorova T.A."/>
<person name="Akimov V."/>
<person name="Henningsen J."/>
<person name="Johansen P.T."/>
<person name="Kratchmarova I."/>
<person name="Kassem M."/>
<person name="Mann M."/>
<person name="Olsen J.V."/>
<person name="Blagoev B."/>
</authorList>
<dbReference type="PubMed" id="21406692"/>
<dbReference type="DOI" id="10.1126/scisignal.2001570"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-518; SER-527 AND SER-530</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="73">
<citation type="journal article" date="2012" name="Cancer Res." volume="72" first="2275" last="2284">
<title>The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.</title>
<authorList>
<person name="Rabellino A."/>
<person name="Carter B."/>
<person name="Konstantinidou G."/>
<person name="Wu S.Y."/>
<person name="Rimessi A."/>
<person name="Byers L.A."/>
<person name="Heymach J.V."/>
<person name="Girard L."/>
<person name="Chiang C.M."/>
<person name="Teruya-Feldstein J."/>
<person name="Scaglioni P.P."/>
</authorList>
<dbReference type="PubMed" id="22406621"/>
<dbReference type="DOI" id="10.1158/0008-5472.can-11-3159"/>
</citation>
<scope>SUMOYLATION AT LYS-65 AND LYS-160</scope>
<scope>PHOSPHORYLATION AT SER-565</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH PIAS1; PIAS2 AND CSNK2A1</scope>
</reference>
<reference key="74">
<citation type="journal article" date="2012" name="Cell Death Differ." volume="19" first="926" last="936">
<title>MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs.</title>
<authorList>
<person name="Peche L.Y."/>
<person name="Scolz M."/>
<person name="Ladelfa M.F."/>
<person name="Monte M."/>
<person name="Schneider C."/>
</authorList>
<dbReference type="PubMed" id="22117195"/>
<dbReference type="DOI" id="10.1038/cdd.2011.173"/>
</citation>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH MAGEA2</scope>
</reference>
<reference key="75">
<citation type="journal article" date="2012" name="Cell Death Dis." volume="3" first="E247" last="E247">
<title>Role of the promyelocytic leukaemia protein in cell death regulation.</title>
<authorList>
<person name="Salomoni P."/>
<person name="Dvorkina M."/>
<person name="Michod D."/>
</authorList>
<dbReference type="PubMed" id="22237204"/>
<dbReference type="DOI" id="10.1038/cddis.2011.122"/>
</citation>
<scope>REVIEW ON FUNCTION</scope>
</reference>
<reference key="76">
<citation type="journal article" date="2012" name="EMBO J." volume="31" first="95" last="109">
<title>Physical and functional interaction between PML and TBX2 in the establishment of cellular senescence.</title>
<authorList>
<person name="Martin N."/>
<person name="Benhamed M."/>
<person name="Nacerddine K."/>
<person name="Demarque M.D."/>
<person name="van Lohuizen M."/>
<person name="Dejean A."/>
<person name="Bischof O."/>
</authorList>
<dbReference type="PubMed" id="22002537"/>
<dbReference type="DOI" id="10.1038/emboj.2011.370"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH TBX2; TBX3; E2F4 AND RBL2</scope>
</reference>
<reference key="77">
<citation type="journal article" date="2012" name="EMBO J." volume="31" first="1427" last="1439">
<title>PML regulates PER2 nuclear localization and circadian function.</title>
<authorList>
<person name="Miki T."/>
<person name="Xu Z."/>
<person name="Chen-Goodspeed M."/>
<person name="Liu M."/>
<person name="Van Oort-Jansen A."/>
<person name="Rea M.A."/>
<person name="Zhao Z."/>
<person name="Lee C.C."/>
<person name="Chang K.S."/>
</authorList>
<dbReference type="PubMed" id="22274616"/>
<dbReference type="DOI" id="10.1038/emboj.2012.1"/>
</citation>
<scope>FUNCTION IN CIRCADIAN CLOCK</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH PER2</scope>
<scope>ACETYLATION AT LYS-487</scope>
<scope>DEACETYLATION BY SIRT1</scope>
</reference>
<reference key="78">
<citation type="journal article" date="2012" name="Front. Oncol." volume="2" first="210" last="210">
<title>Post-translational modifications of PML: consequences and implications.</title>
<authorList>
<person name="Cheng X."/>
<person name="Kao H.Y."/>
</authorList>
<dbReference type="PubMed" id="23316480"/>
<dbReference type="DOI" id="10.3389/fonc.2012.00210"/>
</citation>
<scope>REVIEW ON PTM</scope>
</reference>
<reference key="79">
<citation type="journal article" date="2012" name="Gastroenterology" volume="142" first="572" last="581">
<title>Beta-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.</title>
<authorList>
<person name="Satow R."/>
<person name="Shitashige M."/>
<person name="Jigami T."/>
<person name="Fukami K."/>
<person name="Honda K."/>
<person name="Kitabayashi I."/>
<person name="Yamada T."/>
</authorList>
<dbReference type="PubMed" id="22155184"/>
<dbReference type="DOI" id="10.1053/j.gastro.2011.11.041"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>SUMOYLATION AT LYS-490</scope>
<scope>INTERACTION WITH HDAC7; RANBP2 AND CTNNB1-TCF7L2 COMPLEX</scope>
</reference>
<reference key="80">
<citation type="journal article" date="2012" name="J. Biochem." volume="152" first="161" last="169">
<title>Moloney murine leukemia virus integrase and reverse transcriptase interact with PML proteins.</title>
<authorList>
<person name="Okino Y."/>
<person name="Inayoshi Y."/>
<person name="Kojima Y."/>
<person name="Kidani S."/>
<person name="Kaneoka H."/>
<person name="Honkawa A."/>
<person name="Higuchi H."/>
<person name="Nishijima K."/>
<person name="Miyake K."/>
<person name="Iijima S."/>
</authorList>
<dbReference type="PubMed" id="22685230"/>
<dbReference type="DOI" id="10.1093/jb/mvs063"/>
</citation>
<scope>INTERACTION WITH MOMLV IN AND RT (MICROBIAL INFECTION)</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="81">
<citation type="journal article" date="2012" name="J. Biol. Chem." volume="287" first="23356" last="23367">
<title>Promyelocytic leukemia protein (PML) regulates endothelial cell network formation and migration in response to tumor necrosis factor alpha (TNFalpha) and interferon alpha (IFNalpha).</title>
<authorList>
<person name="Cheng X."/>
<person name="Liu Y."/>
<person name="Chu H."/>
<person name="Kao H.Y."/>
</authorList>
<dbReference type="PubMed" id="22589541"/>
<dbReference type="DOI" id="10.1074/jbc.m112.340505"/>
</citation>
<scope>FUNCTION</scope>
</reference>
<reference key="82">
<citation type="journal article" date="2012" name="J. Biol. Chem." volume="287" first="30729" last="30742">
<title>Contribution of the C-terminal regions of promyelocytic leukemia protein (PML) isoforms II and V to PML nuclear body formation.</title>
<authorList>
<person name="Geng Y."/>
<person name="Monajembashi S."/>
<person name="Shao A."/>
<person name="Cui D."/>
<person name="He W."/>
<person name="Chen Z."/>
<person name="Hemmerich P."/>
<person name="Tang J."/>
</authorList>
<dbReference type="PubMed" id="22773875"/>
<dbReference type="DOI" id="10.1074/jbc.m112.374769"/>
</citation>
<scope>DOMAIN C-TERMINAL</scope>
</reference>
<reference key="83">
<citation type="journal article" date="2012" name="J. Biomed. Sci." volume="19" first="81" last="81">
<title>The role of PML ubiquitination in human malignancies.</title>
<authorList>
<person name="Chen R.H."/>
<person name="Lee Y.R."/>
<person name="Yuan W.C."/>
</authorList>
<dbReference type="PubMed" id="22935031"/>
<dbReference type="DOI" id="10.1186/1423-0127-19-81"/>
</citation>
<scope>REVIEW ON UBIQUITINATION</scope>
</reference>
<reference key="84">
<citation type="journal article" date="2012" name="J. Cell Biol." volume="199" first="49" last="63">
<title>PML promotes MHC class II gene expression by stabilizing the class II transactivator.</title>
<authorList>
<person name="Ulbricht T."/>
<person name="Alzrigat M."/>
<person name="Horch A."/>
<person name="Reuter N."/>
<person name="von Mikecz A."/>
<person name="Steimle V."/>
<person name="Schmitt E."/>
<person name="Kraemer O.H."/>
<person name="Stamminger T."/>
<person name="Hemmerich P."/>
</authorList>
<dbReference type="PubMed" id="23007646"/>
<dbReference type="DOI" id="10.1083/jcb.201112015"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH CIITA</scope>
</reference>
<reference key="85">
<citation type="journal article" date="2012" name="J. Clin. Invest." volume="122" first="3088" last="3100">
<title>A metabolic prosurvival role for PML in breast cancer.</title>
<authorList>
<person name="Carracedo A."/>
<person name="Weiss D."/>
<person name="Leliaert A.K."/>
<person name="Bhasin M."/>
<person name="de Boer V.C."/>
<person name="Laurent G."/>
<person name="Adams A.C."/>
<person name="Sundvall M."/>
<person name="Song S.J."/>
<person name="Ito K."/>
<person name="Finley L.S."/>
<person name="Egia A."/>
<person name="Libermann T."/>
<person name="Gerhart-Hines Z."/>
<person name="Puigserver P."/>
<person name="Haigis M.C."/>
<person name="Maratos-Flier E."/>
<person name="Richardson A.L."/>
<person name="Schafer Z.T."/>
<person name="Pandolfi P.P."/>
</authorList>
<dbReference type="PubMed" id="22886304"/>
<dbReference type="DOI" id="10.1172/jci62129"/>
</citation>
<scope>FUNCTION</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="86">
<citation type="journal article" date="2012" name="J. Virol." volume="86" first="11209" last="11222">
<title>Herpes simplex virus 1 ubiquitin ligase ICP0 interacts with PML isoform I and induces its SUMO-independent degradation.</title>
<authorList>
<person name="Cuchet-Lourenco D."/>
<person name="Vanni E."/>
<person name="Glass M."/>
<person name="Orr A."/>
<person name="Everett R.D."/>
</authorList>
<dbReference type="PubMed" id="22875967"/>
<dbReference type="DOI" id="10.1128/jvi.01145-12"/>
</citation>
<scope>INTERACTION WITH HHV-1 ICP0 (MICROBIAL INFECTION)</scope>
</reference>
<reference key="87">
<citation type="journal article" date="2012" name="PLoS ONE" volume="7" first="E37470" last="E37470">
<title>TRIM16 acts as an E3 ubiquitin ligase and can heterodimerize with other TRIM family members.</title>
<authorList>
<person name="Bell J.L."/>
<person name="Malyukova A."/>
<person name="Holien J.K."/>
<person name="Koach J."/>
<person name="Parker M.W."/>
<person name="Kavallaris M."/>
<person name="Marshall G.M."/>
<person name="Cheung B.B."/>
</authorList>
<dbReference type="PubMed" id="22629402"/>
<dbReference type="DOI" id="10.1371/journal.pone.0037470"/>
</citation>
<scope>INTERACTION WITH TRIM16</scope>
</reference>
<reference key="88">
<citation type="journal article" date="2013" name="J. Proteome Res." volume="12" first="260" last="271">
<title>Toward a comprehensive characterization of a human cancer cell phosphoproteome.</title>
<authorList>
<person name="Zhou H."/>
<person name="Di Palma S."/>
<person name="Preisinger C."/>
<person name="Peng M."/>
<person name="Polat A.N."/>
<person name="Heck A.J."/>
<person name="Mohammed S."/>
</authorList>
<dbReference type="PubMed" id="23186163"/>
<dbReference type="DOI" id="10.1021/pr300630k"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36; SER-38; SER-48; SER-403; SER-505; SER-512; SER-518; SER-527; SER-530 AND THR-867</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
<tissue>Erythroleukemia</tissue>
</source>
</reference>
<reference key="89">
<citation type="journal article" date="2013" name="Oncogene" volume="32" first="3156" last="3164">
<title>BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction.</title>
<authorList>
<person name="Yang Q."/>
<person name="Liao L."/>
<person name="Deng X."/>
<person name="Chen R."/>
<person name="Gray N.S."/>
<person name="Yates J.R. III"/>
<person name="Lee J.D."/>
</authorList>
<dbReference type="PubMed" id="22869143"/>
<dbReference type="DOI" id="10.1038/onc.2012.332"/>
</citation>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH MDM2 AND MAPK7</scope>
</reference>
<reference key="90">
<citation type="journal article" date="2013" name="Oncogene" volume="32" first="3819" last="3828">
<title>The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein.</title>
<authorList>
<person name="Guan D."/>
<person name="Factor D."/>
<person name="Liu Y."/>
<person name="Wang Z."/>
<person name="Kao H.Y."/>
</authorList>
<dbReference type="PubMed" id="22945642"/>
<dbReference type="DOI" id="10.1038/onc.2012.406"/>
</citation>
<scope>UBIQUITINATION BY UHRF1</scope>
</reference>
<reference key="91">
<citation type="journal article" date="2012" name="PLoS ONE" volume="7" first="E44949" last="E44949">
<title>Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.</title>
<authorList>
<person name="Maroui M.A."/>
<person name="Kheddache-Atmane S."/>
<person name="El Asmi F."/>
<person name="Dianoux L."/>
<person name="Aubry M."/>
<person name="Chelbi-Alix M.K."/>
</authorList>
<dbReference type="PubMed" id="23028697"/>
<dbReference type="DOI" id="10.1371/journal.pone.0044949"/>
</citation>
<scope>SUMOYLATION</scope>
<scope>INTERACTION WITH RNF4</scope>
<scope>DOMAIN SIM</scope>
</reference>
<reference key="92">
<citation type="journal article" date="2013" name="Biochem. Biophys. Res. Commun." volume="430" first="592" last="597">
<title>PML tumor suppressor protein is required for HCV production.</title>
<authorList>
<person name="Kuroki M."/>
<person name="Ariumi Y."/>
<person name="Hijikata M."/>
<person name="Ikeda M."/>
<person name="Dansako H."/>
<person name="Wakita T."/>
<person name="Shimotohno K."/>
<person name="Kato N."/>
</authorList>
<dbReference type="PubMed" id="23219818"/>
<dbReference type="DOI" id="10.1016/j.bbrc.2012.11.108"/>
</citation>
<scope>FUNCTION</scope>
</reference>
<reference key="93">
<citation type="journal article" date="2013" name="Blood" volume="121" first="3185" last="3194">
<title>Selective inhibition of the NLRP3 inflammasome by targeting to promyelocytic leukemia protein in mouse and human.</title>
<authorList>
<person name="Lo Y.H."/>
<person name="Huang Y.W."/>
<person name="Wu Y.H."/>
<person name="Tsai C.S."/>
<person name="Lin Y.C."/>
<person name="Mo S.T."/>
<person name="Kuo W.C."/>
<person name="Chuang Y.T."/>
<person name="Jiang S.T."/>
<person name="Shih H.M."/>
<person name="Lai M.Z."/>
</authorList>
<dbReference type="PubMed" id="23430110"/>
<dbReference type="DOI" id="10.1182/blood-2012-05-432104"/>
</citation>
<scope>INTERACTION WITH NLRP3</scope>
</reference>
<reference key="94">
<citation type="journal article" date="2013" name="J. Virol." volume="87" first="965" last="977">
<title>The adenoviral oncogene E1A-13S interacts with a specific isoform of the tumor suppressor PML to enhance viral transcription.</title>
<authorList>
<person name="Berscheminski J."/>
<person name="Groitl P."/>
<person name="Dobner T."/>
<person name="Wimmer P."/>
<person name="Schreiner S."/>
</authorList>
<dbReference type="PubMed" id="23135708"/>
<dbReference type="DOI" id="10.1128/jvi.02023-12"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH HUMAN ADENOVIRUS 2 E1A</scope>
</reference>
<reference key="95">
<citation type="journal article" date="2013" name="Proc. Natl. Acad. Sci. U.S.A." volume="110" first="3895" last="3900">
<title>MOZ increases p53 acetylation and premature senescence through its complex formation with PML.</title>
<authorList>
<person name="Rokudai S."/>
<person name="Laptenko O."/>
<person name="Arnal S.M."/>
<person name="Taya Y."/>
<person name="Kitabayashi I."/>
<person name="Prives C."/>
</authorList>
<dbReference type="PubMed" id="23431171"/>
<dbReference type="DOI" id="10.1073/pnas.1300490110"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH KAT6A</scope>
</reference>
<reference key="96">
<citation type="journal article" date="2014" name="J. Proteomics" volume="96" first="253" last="262">
<title>An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.</title>
<authorList>
<person name="Bian Y."/>
<person name="Song C."/>
<person name="Cheng K."/>
<person name="Dong M."/>
<person name="Wang F."/>
<person name="Huang J."/>
<person name="Sun D."/>
<person name="Wang L."/>
<person name="Ye M."/>
<person name="Zou H."/>
</authorList>
<dbReference type="PubMed" id="24275569"/>
<dbReference type="DOI" id="10.1016/j.jprot.2013.11.014"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-8; SER-36; SER-403; SER-518; SER-527 AND SER-530</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Liver</tissue>
</source>
</reference>
<reference key="97">
<citation type="journal article" date="2014" name="Nat. Struct. Mol. Biol." volume="21" first="927" last="936">
<title>Uncovering global SUMOylation signaling networks in a site-specific manner.</title>
<authorList>
<person name="Hendriks I.A."/>
<person name="D'Souza R.C."/>
<person name="Yang B."/>
<person name="Verlaan-de Vries M."/>
<person name="Mann M."/>
<person name="Vertegaal A.C."/>
</authorList>
<dbReference type="PubMed" id="25218447"/>
<dbReference type="DOI" id="10.1038/nsmb.2890"/>
</citation>
<scope>SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-65; LYS-380 AND LYS-490</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="98">
<citation type="journal article" date="2015" name="Cell Rep." volume="10" first="1778" last="1791">
<title>SUMO-2 orchestrates chromatin modifiers in response to DNA damage.</title>
<authorList>
<person name="Hendriks I.A."/>
<person name="Treffers L.W."/>
<person name="Verlaan-de Vries M."/>
<person name="Olsen J.V."/>
<person name="Vertegaal A.C."/>
</authorList>
<dbReference type="PubMed" id="25772364"/>
<dbReference type="DOI" id="10.1016/j.celrep.2015.02.033"/>
</citation>
<scope>SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-65; LYS-160 AND LYS-490</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="99">
<citation type="journal article" date="2015" name="Mol. Cell. Proteomics" volume="14" first="1419" last="1434">
<title>System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.</title>
<authorList>
<person name="Xiao Z."/>
<person name="Chang J.G."/>
<person name="Hendriks I.A."/>
<person name="Sigurdsson J.O."/>
<person name="Olsen J.V."/>
<person name="Vertegaal A.C."/>
</authorList>
<dbReference type="PubMed" id="25755297"/>
<dbReference type="DOI" id="10.1074/mcp.o114.044792"/>
</citation>
<scope>SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-65; LYS-160; LYS-380; LYS-394; LYS-478 AND LYS-490</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="100">
<citation type="journal article" date="2016" name="Oncogene" volume="35" first="69" last="82">
<title>PML isoforms IV and V contribute to adenovirus-mediated oncogenic transformation by functionally inhibiting the tumor-suppressor p53.</title>
<authorList>
<person name="Wimmer P."/>
<person name="Berscheminski J."/>
<person name="Blanchette P."/>
<person name="Groitl P."/>
<person name="Branton P.E."/>
<person name="Hay R.T."/>
<person name="Dobner T."/>
<person name="Schreiner S."/>
</authorList>
<dbReference type="PubMed" id="25772236"/>
<dbReference type="DOI" id="10.1038/onc.2015.63"/>
</citation>
<scope>INTERACTION OF PML-4 AND PML-5 WITH HADV5 E1B-55K (MICROBIAL INFECTION)</scope>
</reference>
<reference key="101">
<citation type="journal article" date="2016" name="Sci. Rep." volume="6" first="26509" last="26509">
<title>SUMO5, a novel poly-sumo isoform, regulates pml nuclear bodies.</title>
<authorList>
<person name="Liang Y.C."/>
<person name="Lee C.C."/>
<person name="Yao Y.L."/>
<person name="Lai C.C."/>
<person name="Schmitz M.L."/>
<person name="Yang W.M."/>
</authorList>
<dbReference type="PubMed" id="27211601"/>
<dbReference type="DOI" id="10.1038/srep26509"/>
</citation>
<scope>SUMOYLATION AT LYS-160; LYS-380; LYS-400; LYS-490 AND LYS-497</scope>
<scope>MUTAGENESIS OF LYS-65; LYS-160; LYS-380; LYS-400; LYS-490 AND LYS-497</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="102">
<citation type="journal article" date="2017" name="Nat. Commun." volume="8" first="363" last="363">
<title>HSP70-Hrd1 axis precludes the oncorepressor potential of N-terminal misfolded Blimp-1s in lymphoma cells.</title>
<authorList>
<person name="Wang W.F."/>
<person name="Yan L."/>
<person name="Liu Z."/>
<person name="Liu L.X."/>
<person name="Lin J."/>
<person name="Liu Z.Y."/>
<person name="Chen X.P."/>
<person name="Zhang W."/>
<person name="Xu Z.Z."/>
<person name="Shi T."/>
<person name="Li J.M."/>
<person name="Zhao Y.L."/>
<person name="Meng G."/>
<person name="Xia Y."/>
<person name="Li J.Y."/>
<person name="Zhu J."/>
</authorList>
<dbReference type="PubMed" id="28842558"/>
<dbReference type="DOI" id="10.1038/s41467-017-00476-w"/>
</citation>
<scope>INTERACTION WITH PRDM1</scope>
</reference>
<reference key="103">
<citation type="journal article" date="2017" name="Nat. Struct. Mol. Biol." volume="24" first="325" last="336">
<title>Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.</title>
<authorList>
<person name="Hendriks I.A."/>
<person name="Lyon D."/>
<person name="Young C."/>
<person name="Jensen L.J."/>
<person name="Vertegaal A.C."/>
<person name="Nielsen M.L."/>
</authorList>
<dbReference type="PubMed" id="28112733"/>
<dbReference type="DOI" id="10.1038/nsmb.3366"/>
</citation>
<scope>SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-65; LYS-160; LYS-380; LYS-394; LYS-401; LYS-460; LYS-476; LYS-478; LYS-487; LYS-490 AND LYS-497</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="104">
<citation type="journal article" date="1995" name="EMBO J." volume="14" first="1532" last="1541">
<title>The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML.</title>
<authorList>
<person name="Borden K.L.B."/>
<person name="Boddy M.N."/>
<person name="Lally J."/>
<person name="O'Reilly N.J."/>
<person name="Martin S."/>
<person name="Howe K."/>
<person name="Solomon E."/>
<person name="Freemont P.S."/>
</authorList>
<dbReference type="PubMed" id="7729428"/>
<dbReference type="DOI" id="10.1002/j.1460-2075.1995.tb07139.x"/>
</citation>
<scope>STRUCTURE BY NMR OF 49-104</scope>
</reference>
<comment type="function">
<text>Functions via its association with PML-nuclear bodies (PML-NBs) in a wide range of important cellular processes, including tumor suppression, transcriptional regulation, apoptosis, senescence, DNA damage response, and viral defense mechanisms. Acts as the scaffold of PML-NBs allowing other proteins to shuttle in and out, a process which is regulated by SUMO-mediated modifications and interactions. Isoform PML-4 has a multifaceted role in the regulation of apoptosis and growth suppression: activates RB1 and inhibits AKT1 via interactions with PP1 and PP2A phosphatases respectively, negatively affects the PI3K pathway by inhibiting MTOR and activating PTEN, and positively regulates p53/TP53 by acting at different levels (by promoting its acetylation and phosphorylation and by inhibiting its MDM2-dependent degradation). Isoform PML-4 also: acts as a transcriptional repressor of TBX2 during cellular senescence and the repression is dependent on a functional RBL2/E2F4 repressor complex, regulates double-strand break repair in gamma-irradiation-induced DNA damage responses via its interaction with WRN, acts as a negative regulator of telomerase by interacting with TERT, and regulates PER2 nuclear localization and circadian function. Isoform PML-6 inhibits specifically the activity of the tetrameric form of PKM. The nuclear isoforms (isoform PML-1, isoform PML-2, isoform PML-3, isoform PML-4 and isoform PML-5) in concert with SATB1 are involved in local chromatin-loop remodeling and gene expression regulation at the MHC-I locus. Isoform PML-2 is required for efficient IFN-gamma induced MHC II gene transcription via regulation of CIITA. Cytoplasmic PML is involved in the regulation of the TGF-beta signaling pathway. PML also regulates transcription activity of ELF4 and can act as an important mediator for TNF-alpha- and IFN-alpha-mediated inhibition of endothelial cell network formation and migration.</text>
</comment>
<comment type="function">
<text>Exhibits antiviral activity against both DNA and RNA viruses. The antiviral activity can involve one or several isoform(s) and can be enhanced by the permanent PML-NB-associated protein DAXX or by the recruitment of p53/TP53 within these structures. Isoform PML-4 restricts varicella zoster virus (VZV) via sequestration of virion capsids in PML-NBs thereby preventing their nuclear egress and inhibiting formation of infectious virus particles. The sumoylated isoform PML-4 restricts rabies virus by inhibiting viral mRNA and protein synthesis. The cytoplasmic isoform PML-14 can restrict herpes simplex virus-1 (HHV-1) replication by sequestering the viral E3 ubiquitin-protein ligase ICP0 in the cytoplasm. Isoform PML-6 shows restriction activity towards human cytomegalovirus (HCMV) and influenza A virus strains PR8(H1N1) and ST364(H3N2). Sumoylated isoform PML-4 and isoform PML-12 show antiviral activity against encephalomyocarditis virus (EMCV) by promoting nuclear sequestration of viral polymerase (P3D-POL) within PML NBs. Isoform PML-3 exhibits antiviral activity against poliovirus by inducing apoptosis in infected cells through the recruitment and the activation of p53/TP53 in the PML-NBs. Isoform PML-3 represses human foamy virus (HFV) transcription by complexing the HFV transactivator, bel1/tas, preventing its binding to viral DNA. PML may positively regulate infectious hepatitis C viral (HCV) production and isoform PML-2 may enhance adenovirus transcription.</text>
</comment>
<comment type="subunit">
<text evidence="21 22 23 25 28 29 31 32 33 34 35 36 37 38 39 40 42 43 45 48 49 50 51 52 56 59 60 61 62 63 64 65 68 70 71 73 74 77 79">Key component of PML bodies. PML bodies are formed by the interaction of PML homodimers (via SUMO-binding motif) with sumoylated PML, leading to the assembly of higher oligomers. Several types of PML bodies have been observed. PML bodies can form hollow spheres that can sequester target proteins inside. Interacts (via SUMO-binding motif) with sumoylated proteins. Interacts (via C-terminus) with p53/TP53. Recruits p53/TP53 and CHEK2 into PML bodies, which promotes p53/TP53 phosphorylation at 'Ser-20' and prevents its proteasomal degradation. Interacts with MDM2, and sequesters MDM2 in the nucleolus, thereby preventing ubiquitination of p53/TP53. Interaction with PML-RARA oncoprotein and certain viral proteins causes disassembly of PML bodies and abolishes the normal PML function. Interacts with HIPK2, TERT, SIRT1, TOPBP1, TRIM27 and TRIM69. Interacts with ELF4 (via C-terminus). Interacts with ITPR3. Interacts (in the cytoplasm) with TGFBR1, TGFBR2 and PKM. Interacts (via the coiled-coil domain and when sumoylated) with SATB1. Interacts with UBE2I; the interaction is enhanced by arsenic binding. Interacts (PML-RARA oncoprotein, via the coiled-coil domain) with UBE2I; the interaction is enhanced by arsenic binding and is required for PML-RARA oncoprotein sumoylation and inhibition of RARA transactivational activity. Interacts with RB1, PPP1A, SMAD2, SMAD3, DAXX, RPL11 and MTOR. Interacts with PPARGC1A and KAT2A. Interacts with CSNK2A1 and CSNK2A3. Interacts with ANKRD2; the interaction is direct. Interacts (via SUMO-interacting motif) with sumoylated MORC3 (PubMed:20501696). Isoform PML-1, isoform PML-2, isoform PML-3, isoform PML-4, isoform PML-5 and isoform PML-6 interact with RNF4. Isoform PML-1 interacts with NLRP3. Isoform PML-1, isoform PML-2, isoform PML-3, isoform PML-4 and isoform PML-5 interact with MAGEA2, RBL2, PER2 and E2F4. Isoform PML-2 interacts with CIITA. Isoform PML-2, isoform PML-3 and isoform PML-4 interact with TBX2. Isoform PML-4 interacts with RANBP2, HDAC7, KAT6A, WRN, PIN1, TBX3 and phosphorylated MAPK1/ERK2. Isoform PML-4 interacts with the CTNNB1 and TCF7L2/TCF4 complex. Isoform PML-4 preferentially interacts with MAPK7/BMK1 although other isoforms (isoform PML-1, isoform PML-2, isoform PML-3 and isoform PML-6) also interact with it. Isoform PML-12 interacts with PIAS1, PIAS2 (isoform PIAS2-alpha) and CSNK2A1/CK2. Interacts with TRIM16. Interacts with PRDM1/Blimp-1 (PubMed:28842558).</text>
</comment>
<comment type="subunit">
<text evidence="78">(Microbial infection) Interacts with Lassa virus Z protein and rabies virus phosphoprotein.</text>
</comment>
<comment type="subunit">
<text evidence="69">(Microbial infection) Isoform PML-1 interacts with herpes simplex virus-1/HHV-1 ICP0.</text>
</comment>
<comment type="subunit">
<text evidence="72">(Microbial infection) Isoform PML-2 interacts with human adenovirus 2 E1A and this interaction stimulates E1A-dependent transcriptional activation.</text>
</comment>
<comment type="subunit">
<text evidence="55">(Microbial infection) Isoform PML-4 interacts with VZV capsid protein VP26/ORF23 capsid protein.</text>
</comment>
<comment type="subunit">
<text evidence="58">(Microbial infection) The sumoylated isoform PML-4 interacts with encephalomyocarditis virus (EMCV) RNA-directed RNA polymerase 3D-POL (P3D-POL).</text>
</comment>
<comment type="subunit">
<text evidence="66">(Microbial infection) Isoform PML-6 interacts with moloney murine leukemia virus (MoMLV) integrase (IN) and reverse transcriptase (RT).</text>
</comment>
<comment type="subunit">
<text evidence="53 72 75">(Microbial infection) Isoform PML-4 and isoform PML-5 interact with human adenovirus 5 E1B-55K protein; these interactions promote efficient subnuclear targeting of E1B-55K to PML nuclear bodies.</text>
</comment>
<comment type="subunit">
<text evidence="27">(Microbial infection) Isoform PML-3 interacts with human foamy virus bel1/tas and bet.</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-295890">
<id>P29590</id>
</interactant>
<interactant intactId="EBI-347804">
<id>P68400</id>
<label>CSNK2A1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-295890">
<id>P29590</id>
</interactant>
<interactant intactId="EBI-77321">
<id>Q9UER7</id>
<label>DAXX</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-295890">
<id>P29590</id>
</interactant>
<interactant intactId="EBI-494743">
<id>P25445</id>
<label>FAS</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-295890">
<id>P29590</id>
</interactant>
<interactant intactId="EBI-714379">
<id>Q9Y2M5</id>
<label>KLHL20</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>9</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-295890">
<id>P29590</id>
</interactant>
<interactant intactId="EBI-1213983">
<id>Q13164</id>
<label>MAPK7</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-295890">
<id>P29590</id>
</interactant>
<interactant intactId="EBI-389668">
<id>Q00987</id>
<label>MDM2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-295890">
<id>P29590</id>
</interactant>
<interactant intactId="EBI-1054296">
<id>O15055</id>
<label>PER2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-295890">
<id>P29590</id>
</interactant>
<interactant intactId="EBI-348380">
<id>P25788</id>
<label>PSMA3</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-295890">
<id>P29590</id>
</interactant>
<interactant intactId="EBI-80140">
<id>P63165</id>
<label>SUMO1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-295890">
<id>P29590</id>
</interactant>
<interactant intactId="EBI-2853051">
<id>Q13207</id>
<label>TBX2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-295890">
<id>P29590</id>
</interactant>
<interactant intactId="EBI-310727">
<id>Q6N021</id>
<label>TET2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-295890">
<id>P29590</id>
</interactant>
<interactant intactId="EBI-714215">
<id>Q15583</id>
<label>TGIF1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-295890">
<id>P29590</id>
</interactant>
<interactant intactId="EBI-366083">
<id>P04637</id>
<label>TP53</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-295890">
<id>P29590</id>
</interactant>
<interactant intactId="EBI-711925">
<id>Q05516</id>
<label>ZBTB16</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>7</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-295890">
<id>P29590</id>
</interactant>
<interactant intactId="EBI-6692904">
<id>Q8UN00</id>
<label>gag-pro-pol</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-295890">
<id>P29590</id>
</interactant>
<interactant intactId="EBI-1927377">
<id>P03243-1</id>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-295890">
<id>P29590</id>
</interactant>
<interactant intactId="EBI-6377335">
<id>PRO_0000037566</id>
<dbReference type="UniProtKB" id="P27958"/>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-303996">
<id>P29590-2</id>
</interactant>
<interactant intactId="EBI-1927377">
<id>P03243-1</id>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-8099068">
<id>P29590-3</id>
</interactant>
<interactant intactId="EBI-6398911">
<id>P04489</id>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-304008">
<id>P29590-5</id>
</interactant>
<interactant intactId="EBI-389668">
<id>Q00987</id>
<label>MDM2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-304008">
<id>P29590-5</id>
</interactant>
<interactant intactId="EBI-1772203">
<id>O14746</id>
<label>TERT</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>7</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-304008">
<id>P29590-5</id>
</interactant>
<interactant intactId="EBI-711925">
<id>Q05516</id>
<label>ZBTB16</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-304008">
<id>P29590-5</id>
</interactant>
<interactant intactId="EBI-1927377">
<id>P03243-1</id>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-304008">
<id>P29590-5</id>
</interactant>
<interactant intactId="EBI-6726189">
<id>PRO_0000039791</id>
<dbReference type="UniProtKB" id="P03304"/>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-6861318">
<id>P29590-9</id>
</interactant>
<interactant intactId="EBI-80140">
<id>P63165</id>
<label>SUMO1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-12368281">
<id>P29590-13</id>
</interactant>
<interactant intactId="EBI-12368281">
<id>P29590-13</id>
<label>PML</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location>Nucleus</location>
</subcellularLocation>
<subcellularLocation>
<location>Nucleus</location>
<location>Nucleoplasm</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="76">Cytoplasm</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="51 76">Nucleus</location>
<location evidence="51 76">PML body</location>
</subcellularLocation>
<subcellularLocation>
<location>Nucleus</location>
<location>Nucleolus</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="16">Endoplasmic reticulum membrane</location>
<topology evidence="16">Peripheral membrane protein</topology>
<orientation evidence="16">Cytoplasmic side</orientation>
</subcellularLocation>
<subcellularLocation>
<location>Early endosome membrane</location>
<topology>Peripheral membrane protein</topology>
<orientation>Cytoplasmic side</orientation>
</subcellularLocation>
<text>Isoform PML-1 can shuttle between the nucleus and cytoplasm. Isoform PML-2, isoform PML-3, isoform PML-4, isoform PML-5 and isoform PML-6 are nuclear isoforms whereas isoform PML-7 and isoform PML-14 lacking the nuclear localization signal are cytoplasmic isoforms. Detected in the nucleolus after DNA damage. Acetylation at Lys-487 is essential for its nuclear localization. Within the nucleus, most of PML is expressed in the diffuse nuclear fraction of the nucleoplasm and only a small fraction is found in the matrix-associated nuclear bodies (PML-NBs). The transfer of PML from the nucleoplasm to PML-NBs depends on its phosphorylation and sumoylation. The B1 box and the RING finger are also required for the localization in PML-NBs. Also found in specific membrane structures termed mitochondria-associated membranes (MAMs) which connect the endoplasmic reticulum (ER) and the mitochondria. Sequestered in the cytoplasm by interaction with rabies virus phosphoprotein.</text>
</comment>
<comment type="alternative products">
<event type="alternative splicing"/>
<isoform>
<id>P29590-1</id>
<name>PML-1</name>
<name>PML-I</name>
<name>TRIM19alpha</name>
<sequence type="displayed"/>
</isoform>
<isoform>
<id>P29590-8</id>
<name>PML-2</name>
<name>PML-II</name>
<name>TRIM19kappa</name>
<sequence type="described" ref="VSP_040595"/>
</isoform>
<isoform>
<id>P29590-9</id>
<name>PML-3</name>
<name>PML-III</name>
<sequence type="described" ref="VSP_040596 VSP_040597"/>
</isoform>
<isoform>
<id>P29590-5</id>
<name>PML-4</name>
<name>PML-IV</name>
<name>PML-X</name>
<name>TRIM19zeta</name>
<sequence type="described" ref="VSP_005744 VSP_005745"/>
</isoform>
<isoform>
<id>P29590-2</id>
<name>PML-5</name>
<name>PML-2</name>
<name>PML-V</name>
<name>TRIM19beta</name>
<sequence type="described" ref="VSP_005739 VSP_005740"/>
</isoform>
<isoform>
<id>P29590-4</id>
<name>PML-6</name>
<name>PML-3B</name>
<name>PML-VI</name>
<name>TRIM19epsilon</name>
<sequence type="described" ref="VSP_005742 VSP_005743"/>
</isoform>
<isoform>
<id>P29590-10</id>
<name>PML-7</name>
<name>PML-VII</name>
<name>TRIM19theta</name>
<sequence type="described" ref="VSP_040591 VSP_040594"/>
</isoform>
<isoform>
<id>P29590-3</id>
<name>PML-8</name>
<name>PML-2G</name>
<name>PML-IIG</name>
<name>TRIM19gamma</name>
<sequence type="described" ref="VSP_005741"/>
</isoform>
<isoform>
<id>P29590-11</id>
<name>PML-11</name>
<name>PML-1A</name>
<name>PML-IA</name>
<sequence type="described" ref="VSP_040590"/>
</isoform>
<isoform>
<id>P29590-12</id>
<name>PML-12</name>
<name>PML-4A</name>
<name>PML-IVA</name>
<name>TRIM19lambda</name>
<sequence type="described" ref="VSP_040590 VSP_005744 VSP_005745"/>
</isoform>
<isoform>
<id>P29590-13</id>
<name>PML-13</name>
<name>PML-2A</name>
<name>PML-IIA</name>
<sequence type="described" ref="VSP_040590 VSP_040595"/>
</isoform>
<isoform>
<id>P29590-14</id>
<name>PML-14</name>
<name>PML-6B</name>
<name>PML-VIB</name>
<name>TRIM19eta</name>
<name>TRIM19iota</name>
<sequence type="described" ref="VSP_040592 VSP_040593"/>
</isoform>
</comment>
<comment type="induction">
<text>By interferons alpha, beta and gamma. Up-regulated by IRF3 and p53/TP53.</text>
</comment>
<comment type="domain">
<text evidence="45">The coiled-coil domain mediates a strong homo/multidimerization activity essential for core assembly of PML-NBs. Interacts with PKM via its coiled-coil domain (PubMed:18298799).</text>
</comment>
<comment type="domain">
<text evidence="64">The B box-type zinc binding domain and the coiled-coil domain mediate its interaction with PIAS1.</text>
</comment>
<comment type="domain">
<text evidence="27">Binds arsenic via the RING-type zinc finger. The RING-type zinc finger is essential for its interaction with HFV bel1/tas (PubMed:11432836).</text>
</comment>
<comment type="domain">
<text evidence="67">The unique C-terminal domains of isoform PML-2 and isoform PML-5 play an important role in regulating the localization, assembly dynamics, and functions of PML-NBs.</text>
</comment>
<comment type="domain">
<text evidence="71">The Sumo interaction motif (SIM) is required for efficient ubiquitination, recruitment of proteasome components within PML-NBs and PML degradation in response to arsenic trioxide.</text>
</comment>
<comment type="PTM">
<text evidence="17 46 57 60">Ubiquitinated; mediated by RNF4, RNF111, UHRF1, UBE3A/E6AP, BCR(KLHL20) E3 ubiquitin ligase complex E3 ligase complex, SIAH1 or SIAH2 and leading to subsequent proteasomal degradation (PubMed:18408734, PubMed:21840486, PubMed:22033920). Ubiquitination by BCR(KLHL20) E3 ubiquitin ligase complex E3 ligase complex requires CDK1/2-mediated phosphorylation at Ser-518 which in turn is recognized by prolyl-isopeptidase PIN1 and PIN1-catalyzed isomerization further potentiates PML interaction with KLHL20 (PubMed:21840486, PubMed:22033920). 'Lys-6'-, 'Lys-11'-, 'Lys-48'- and 'Lys-63'-linked polyubiquitination by RNF4 is polysumoylation-dependent (PubMed:18408734). Ubiquitination by RNF111 is polysumoylation-dependent (By similarity).</text>
</comment>
<comment type="PTM">
<text evidence="30 46 54 62 64 76 80">Sumoylation regulates PML's: stability in response to extracellular or intracellular stimuli, transcription directly and indirectly, through sequestration of or dissociation of the transcription factors from PML-NBs, ability to regulate apoptosis and its anti-viral activities. It is also essential for: maintaining proper PML nuclear bodies (PML-NBs) structure and normal function, recruitment of components of PML-NBs, the turnover and retention of PML in PML-NBs and the integrity of PML-NBs. Undergoes 'Lys-11'-linked sumoylation. Sumoylation on all three sites (Lys-65, Lys-160 and Lys-490) is required for nuclear body formation. Sumoylation on Lys-160 is a prerequisite for sumoylation on Lys-65. Lys-65 and Lys-160 are sumoylated by PISA1 and PIAS2. PIAS1-mediated sumoylation of PML promotes its interaction with CSNK2A1/CK2 and phosphorylation at Ser-565 which in turn triggers its ubiquitin-mediated degradation. PIAS1-mediated sumoylation of PML-RARA promotes its ubiquitin-mediated degradation. The PML-RARA fusion protein requires the coiled-coil domain for sumoylation. Sumoylation at Lys-490 by RANBP2 is essential for the proper assembly of PML-NBs. SUMO1P1/SUMO5 conjugated PML at Lys-160, Lys-380, Lys-400, Lys-490 and Lys-497, but Lys-380, Lys-400 and Lys-497 are not key acceptor lysines. SUMO1P1/SUMO5 forms polymeric chain on Lys-160 of PML by successive conjugation at 'Lys-18'; facilitating recruitment of PML-NB components, which enlarges PML. SUMO1P1/SUMO5 conjugation of PML increases SUMO2/3 conjugation, which leads to the recruitment of RNF4 and ubiquitin-dependent disintegration of PML-NBs. SUMO1P1/SUMO5 monoconjugated Lys-490 (PubMed:27211601). DNA damage triggers its sumoylation while some but not all viral infections can abolish sumoylation. Desumoylated by SENP1, SENP2, SENP3, SENP5 and SENP6 (PubMed:27211601, PubMed:12419228, PubMed:21148299). Arsenic induces PML and PML-RARA polysumoylation and their subsequent RNF4-dependent ubiquitination and proteasomal degradation, and is used as treatment in acute promyelocytic leukemia (APL). The nuclear isoforms (isoform PML-1, isoform PML-2, isoform PML-3, isoform PML-4, isoform PML-5 and isoform PML-6) show an increased sumoylation in response to arsenic trioxide. The cytoplasmic isoform PML-7 is not sumoylated.</text>
</comment>
<comment type="PTM">
<text evidence="29 37 46 48 57 60 64">Phosphorylation is a major regulatory mechanism that controls PML protein abundance and the number and size of PML nuclear bodies (PML-NBs). Phosphorylated in response to DNA damage, probably by ATR. HIPK2-mediated phosphorylation at Ser-8, Ser-36 and Ser-38 leads to increased accumulation of PML protein and its sumoylation and is required for the maximal pro-apoptotic activity of PML after DNA damage. CHEK2-mediated phosphorylation at Ser-117 is important for PML-mediated apoptosis following DNA damage. MAPK1-mediated phosphorylations at Ser-403, Ser-505, Ser-527 and Ser-530 and CDK1/2-mediated phosphorylation at Ser-518 promote PIN1-dependent PML degradation. CK2-mediated phosphorylation at Ser-565 primes PML ubiquitination via an unidentified ubiquitin ligase.</text>
</comment>
<comment type="PTM">
<text evidence="47 63">Acetylation at Lys-487 is essential for its nuclear localization. Deacetylated at Lys-487 by SIRT1 and this deacetylation promotes PML control of PER2 nuclear localization.</text>
</comment>
<comment type="disease">
<text evidence="41 44">A chromosomal aberration involving PML may be a cause of acute promyelocytic leukemia (APL). Translocation t(15;17)(q21;q21) with RARA. The PML breakpoints (type A and type B) lie on either side of an alternatively spliced exon.</text>
</comment>
<comment type="miscellaneous">
<molecule>Isoform PML-8</molecule>
<text evidence="90">Non-canonical splice sites. Might alternatively represent a polymorphic variation.</text>
</comment>
<comment type="sequence caution" evidence="90">
<conflict type="erroneous initiation">
<sequence resource="EMBL-CDS" id="AAA60351" version="1"/>
</conflict>
<text>Truncated N-terminus.</text>
</comment>
<comment type="sequence caution" evidence="90">
<conflict type="erroneous initiation">
<sequence resource="EMBL-CDS" id="AAA60352" version="1"/>
</conflict>
<text>Truncated N-terminus.</text>
</comment>
<comment type="sequence caution" evidence="90">
<conflict type="erroneous initiation">
<sequence resource="EMBL-CDS" id="AAA60388" version="1"/>
</conflict>
<text>Truncated N-terminus.</text>
</comment>
<comment type="sequence caution" evidence="90">
<conflict type="erroneous initiation">
<sequence resource="EMBL-CDS" id="AAA60390" version="1"/>
</conflict>
<text>Truncated N-terminus.</text>
</comment>
<comment type="sequence caution" evidence="90">
<conflict type="miscellaneous discrepancy">
<sequence resource="EMBL-CDS" id="BAB62809" version="1"/>
</conflict>
<text>Chimeric cDNA.</text>
</comment>
<comment type="sequence caution" evidence="90">
<conflict type="erroneous initiation">
<sequence resource="EMBL-CDS" id="BAD92648" version="1"/>
</conflict>
<text>Extended N-terminus.</text>
</comment>
<comment type="online information" name="Atlas of Genetics and Cytogenetics in Oncology and Haematology">
<link uri="http://atlasgeneticsoncology.org/Genes/PMLID41.html"/>
</comment>
<dbReference type="EMBL" id="S50913">
<property type="protein sequence ID" value="AAB19601.2"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="M79462">
<property type="protein sequence ID" value="AAA60388.1"/>
<property type="status" value="ALT_INIT"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="M79463">
<property type="protein sequence ID" value="AAA60351.1"/>
<property type="status" value="ALT_INIT"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="M79464">
<property type="protein sequence ID" value="AAA60390.1"/>
<property type="status" value="ALT_INIT"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="X63131">
<property type="protein sequence ID" value="CAA44841.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="M73778">
<property type="protein sequence ID" value="AAA60125.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="M80185">
<property type="protein sequence ID" value="AAA60352.1"/>
<property type="status" value="ALT_INIT"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF230401">
<property type="protein sequence ID" value="AAG50180.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF230402">
<property type="protein sequence ID" value="AAG50181.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF230403">
<property type="protein sequence ID" value="AAG50182.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF230405">
<property type="protein sequence ID" value="AAG50184.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF230406">
<property type="protein sequence ID" value="AAG50185.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF230407">
<property type="protein sequence ID" value="AAG50186.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF230408">
<property type="protein sequence ID" value="AAG50187.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF230409">
<property type="protein sequence ID" value="AAG50188.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF230410">
<property type="protein sequence ID" value="AAG50189.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF230411">
<property type="protein sequence ID" value="AAG50190.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BT009911">
<property type="protein sequence ID" value="AAP88913.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AB209411">
<property type="protein sequence ID" value="BAD92648.1"/>
<property type="status" value="ALT_INIT"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AC013486">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AC108137">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BC000080">
<property type="protein sequence ID" value="AAH00080.2"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC020994">
<property type="protein sequence ID" value="AAH20994.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="X64800">
<property type="protein sequence ID" value="CAA46026.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AB067754">
<property type="protein sequence ID" value="BAB62809.1"/>
<property type="status" value="ALT_SEQ"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS10255.1">
<molecule id="P29590-1"/>
</dbReference>
<dbReference type="CCDS" id="CCDS10256.1">
<molecule id="P29590-10"/>
</dbReference>
<dbReference type="CCDS" id="CCDS10257.1">
<molecule id="P29590-8"/>
</dbReference>
<dbReference type="CCDS" id="CCDS10258.1">
<molecule id="P29590-13"/>
</dbReference>
<dbReference type="CCDS" id="CCDS45297.1">
<molecule id="P29590-5"/>
</dbReference>
<dbReference type="CCDS" id="CCDS45298.1">
<molecule id="P29590-2"/>
</dbReference>
<dbReference type="CCDS" id="CCDS45299.1">
<molecule id="P29590-4"/>
</dbReference>
<dbReference type="CCDS" id="CCDS45300.1">
<molecule id="P29590-14"/>
</dbReference>
<dbReference type="CCDS" id="CCDS58386.1">
<molecule id="P29590-12"/>
</dbReference>
<dbReference type="PIR" id="A40044">
<property type="entry name" value="A40044"/>
</dbReference>
<dbReference type="PIR" id="I38054">
<property type="entry name" value="I38054"/>
</dbReference>
<dbReference type="PIR" id="S19244">
<property type="entry name" value="S19244"/>
</dbReference>
<dbReference type="PIR" id="S42516">
<property type="entry name" value="S42516"/>
</dbReference>
<dbReference type="PIR" id="S44381">
<property type="entry name" value="S44381"/>
</dbReference>
<dbReference type="RefSeq" id="NP_002666.1">
<molecule id="P29590-5"/>
<property type="nucleotide sequence ID" value="NM_002675.3"/>
</dbReference>
<dbReference type="RefSeq" id="NP_150241.2">
<molecule id="P29590-1"/>
<property type="nucleotide sequence ID" value="NM_033238.2"/>
</dbReference>
<dbReference type="RefSeq" id="NP_150242.1">
<molecule id="P29590-8"/>
<property type="nucleotide sequence ID" value="NM_033239.2"/>
</dbReference>
<dbReference type="RefSeq" id="NP_150243.2">
<molecule id="P29590-2"/>
<property type="nucleotide sequence ID" value="NM_033240.2"/>
</dbReference>
<dbReference type="RefSeq" id="NP_150247.2">
<molecule id="P29590-4"/>
<property type="nucleotide sequence ID" value="NM_033244.3"/>
</dbReference>
<dbReference type="RefSeq" id="NP_150249.1">
<molecule id="P29590-14"/>
<property type="nucleotide sequence ID" value="NM_033246.2"/>
</dbReference>
<dbReference type="RefSeq" id="NP_150250.2">
<molecule id="P29590-10"/>
<property type="nucleotide sequence ID" value="NM_033247.2"/>
</dbReference>
<dbReference type="RefSeq" id="NP_150252.1">
<molecule id="P29590-12"/>
<property type="nucleotide sequence ID" value="NM_033249.2"/>
</dbReference>
<dbReference type="RefSeq" id="NP_150253.2">
<molecule id="P29590-13"/>
<property type="nucleotide sequence ID" value="NM_033250.2"/>
</dbReference>
<dbReference type="PDB" id="1BOR">
<property type="method" value="NMR"/>
<property type="chains" value="A=49-104"/>
</dbReference>
<dbReference type="PDB" id="2MVW">
<property type="method" value="NMR"/>
<property type="chains" value="A/B=120-168"/>
</dbReference>
<dbReference type="PDB" id="2MWX">
<property type="method" value="NMR"/>
<property type="chains" value="A=49-104"/>
</dbReference>
<dbReference type="PDB" id="4WJN">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.50"/>
<property type="chains" value="B=547-573"/>
</dbReference>
<dbReference type="PDB" id="4WJO">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.46"/>
<property type="chains" value="B=547-573"/>
</dbReference>
<dbReference type="PDB" id="5YUF">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.60"/>
<property type="chains" value="A/B/C/D=49-99"/>
</dbReference>
<dbReference type="PDB" id="6IMQ">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.06"/>
<property type="chains" value="A/B/C/D=120-168"/>
</dbReference>
<dbReference type="PDB" id="6UYO">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.64"/>
<property type="chains" value="B/D=547-574"/>
</dbReference>
<dbReference type="PDB" id="6UYP">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.42"/>
<property type="chains" value="B=547-574"/>
</dbReference>
<dbReference type="PDB" id="6UYQ">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.50"/>
<property type="chains" value="B=547-574"/>
</dbReference>
<dbReference type="PDB" id="6UYR">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.30"/>
<property type="chains" value="B=547-574"/>
</dbReference>
<dbReference type="PDB" id="6UYS">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.59"/>
<property type="chains" value="B/D=547-574"/>
</dbReference>
<dbReference type="PDB" id="6UYT">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.66"/>
<property type="chains" value="B=547-574"/>
</dbReference>
<dbReference type="PDB" id="6UYU">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.66"/>
<property type="chains" value="B/D=547-574"/>
</dbReference>
<dbReference type="PDB" id="6UYV">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.40"/>
<property type="chains" value="B=547-574"/>
</dbReference>
<dbReference type="PDBsum" id="1BOR"/>
<dbReference type="PDBsum" id="2MVW"/>
<dbReference type="PDBsum" id="2MWX"/>
<dbReference type="PDBsum" id="4WJN"/>
<dbReference type="PDBsum" id="4WJO"/>
<dbReference type="PDBsum" id="5YUF"/>
<dbReference type="PDBsum" id="6IMQ"/>
<dbReference type="PDBsum" id="6UYO"/>
<dbReference type="PDBsum" id="6UYP"/>
<dbReference type="PDBsum" id="6UYQ"/>
<dbReference type="PDBsum" id="6UYR"/>
<dbReference type="PDBsum" id="6UYS"/>
<dbReference type="PDBsum" id="6UYT"/>
<dbReference type="PDBsum" id="6UYU"/>
<dbReference type="PDBsum" id="6UYV"/>
<dbReference type="SMR" id="P29590"/>
<dbReference type="BioGRID" id="111384">
<property type="interactions" value="275"/>
</dbReference>
<dbReference type="CORUM" id="P29590"/>
<dbReference type="DIP" id="DIP-33053N"/>
<dbReference type="IntAct" id="P29590">
<property type="interactions" value="123"/>
</dbReference>
<dbReference type="MINT" id="P29590"/>
<dbReference type="STRING" id="9606.ENSP00000268058"/>
<dbReference type="DrugBank" id="DB01169">
<property type="generic name" value="Arsenic trioxide"/>
</dbReference>
<dbReference type="iPTMnet" id="P29590"/>
<dbReference type="PhosphoSitePlus" id="P29590"/>
<dbReference type="BioMuta" id="PML"/>
<dbReference type="DMDM" id="215274219"/>
<dbReference type="EPD" id="P29590"/>
<dbReference type="jPOST" id="P29590"/>
<dbReference type="MassIVE" id="P29590"/>
<dbReference type="MaxQB" id="P29590"/>
<dbReference type="PaxDb" id="P29590"/>
<dbReference type="PeptideAtlas" id="P29590"/>
<dbReference type="PRIDE" id="P29590"/>
<dbReference type="ProteomicsDB" id="19281"/>
<dbReference type="ProteomicsDB" id="54589">
<molecule id="P29590-1"/>
</dbReference>
<dbReference type="ProteomicsDB" id="54590">
<molecule id="P29590-10"/>
</dbReference>
<dbReference type="ProteomicsDB" id="54591">
<molecule id="P29590-11"/>
</dbReference>
<dbReference type="ProteomicsDB" id="54592">
<molecule id="P29590-12"/>
</dbReference>
<dbReference type="ProteomicsDB" id="54593">
<molecule id="P29590-13"/>
</dbReference>
<dbReference type="ProteomicsDB" id="54594">
<molecule id="P29590-14"/>
</dbReference>
<dbReference type="ProteomicsDB" id="54595">
<molecule id="P29590-2"/>
</dbReference>
<dbReference type="ProteomicsDB" id="54596">
<molecule id="P29590-3"/>
</dbReference>
<dbReference type="ProteomicsDB" id="54597">
<molecule id="P29590-4"/>
</dbReference>
<dbReference type="ProteomicsDB" id="54598">
<molecule id="P29590-5"/>
</dbReference>
<dbReference type="ProteomicsDB" id="54599">
<molecule id="P29590-8"/>
</dbReference>
<dbReference type="ProteomicsDB" id="54600">
<molecule id="P29590-9"/>
</dbReference>
<dbReference type="Antibodypedia" id="1737">
<property type="antibodies" value="575 antibodies"/>
</dbReference>
<dbReference type="DNASU" id="5371"/>
<dbReference type="Ensembl" id="ENST00000268058">
<molecule id="P29590-1"/>
<property type="protein sequence ID" value="ENSP00000268058"/>
<property type="gene ID" value="ENSG00000140464"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000268059">
<molecule id="P29590-8"/>
<property type="protein sequence ID" value="ENSP00000268059"/>
<property type="gene ID" value="ENSG00000140464"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000354026">
<molecule id="P29590-13"/>
<property type="protein sequence ID" value="ENSP00000315434"/>
<property type="gene ID" value="ENSG00000140464"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000359928">
<molecule id="P29590-14"/>
<property type="protein sequence ID" value="ENSP00000353004"/>
<property type="gene ID" value="ENSG00000140464"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000395132">
<molecule id="P29590-10"/>
<property type="protein sequence ID" value="ENSP00000378564"/>
<property type="gene ID" value="ENSG00000140464"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000395135">
<molecule id="P29590-5"/>
<property type="protein sequence ID" value="ENSP00000378567"/>
<property type="gene ID" value="ENSG00000140464"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000435786">
<molecule id="P29590-2"/>
<property type="protein sequence ID" value="ENSP00000395576"/>
<property type="gene ID" value="ENSG00000140464"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000436891">
<molecule id="P29590-4"/>
<property type="protein sequence ID" value="ENSP00000394642"/>
<property type="gene ID" value="ENSG00000140464"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000564428">
<molecule id="P29590-12"/>
<property type="protein sequence ID" value="ENSP00000457023"/>
<property type="gene ID" value="ENSG00000140464"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000565898">
<molecule id="P29590-11"/>
<property type="protein sequence ID" value="ENSP00000455838"/>
<property type="gene ID" value="ENSG00000140464"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000567543">
<molecule id="P29590-14"/>
<property type="protein sequence ID" value="ENSP00000456277"/>
<property type="gene ID" value="ENSG00000140464"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000569477">
<molecule id="P29590-9"/>
<property type="protein sequence ID" value="ENSP00000455612"/>
<property type="gene ID" value="ENSG00000140464"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000569965">
<molecule id="P29590-4"/>
<property type="protein sequence ID" value="ENSP00000456486"/>
<property type="gene ID" value="ENSG00000140464"/>
</dbReference>
<dbReference type="GeneID" id="5371"/>
<dbReference type="KEGG" id="hsa:5371"/>
<dbReference type="UCSC" id="uc002awk.4">
<molecule id="P29590-1"/>
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="5371"/>
<dbReference type="DisGeNET" id="5371"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000140464.19"/>
<dbReference type="GeneCards" id="PML"/>
<dbReference type="HGNC" id="HGNC:9113">
<property type="gene designation" value="PML"/>
</dbReference>
<dbReference type="HPA" id="ENSG00000140464">
<property type="expression patterns" value="Low tissue specificity"/>
</dbReference>
<dbReference type="MalaCards" id="PML"/>
<dbReference type="MIM" id="102578">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="neXtProt" id="NX_P29590"/>
<dbReference type="OpenTargets" id="ENSG00000140464"/>
<dbReference type="Orphanet" id="520">
<property type="disease" value="Acute promyelocytic leukemia"/>
</dbReference>
<dbReference type="PharmGKB" id="PA33439"/>
<dbReference type="eggNOG" id="KOG2177">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00510000048454"/>
<dbReference type="HOGENOM" id="CLU_009136_1_0_1"/>
<dbReference type="InParanoid" id="P29590"/>
<dbReference type="KO" id="K10054"/>
<dbReference type="OMA" id="CCICALL"/>
<dbReference type="OrthoDB" id="421875at2759"/>
<dbReference type="PhylomeDB" id="P29590"/>
<dbReference type="TreeFam" id="TF336434"/>
<dbReference type="PathwayCommons" id="P29590"/>
<dbReference type="Reactome" id="R-HSA-3108214">
<property type="pathway name" value="SUMOylation of DNA damage response and repair proteins"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-3232142">
<property type="pathway name" value="SUMOylation of ubiquitinylation proteins"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6804758">
<property type="pathway name" value="Regulation of TP53 Activity through Acetylation"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-877300">
<property type="pathway name" value="Interferon gamma signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8934593">
<property type="pathway name" value="Regulation of RUNX1 Expression and Activity"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8948747">
<property type="pathway name" value="Regulation of PTEN localization"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-9609690">
<property type="pathway name" value="HCMV Early Events"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-9616222">
<molecule id="P29590-4"/>
<property type="pathway name" value="Transcriptional regulation of granulopoiesis"/>
</dbReference>
<dbReference type="SignaLink" id="P29590"/>
<dbReference type="SIGNOR" id="P29590"/>
<dbReference type="BioGRID-ORCS" id="5371">
<property type="hits" value="10 hits in 877 CRISPR screens"/>
</dbReference>
<dbReference type="ChiTaRS" id="PML">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="P29590"/>
<dbReference type="GeneWiki" id="Promyelocytic_leukemia_protein"/>
<dbReference type="GenomeRNAi" id="5371"/>
<dbReference type="Pharos" id="P29590">
<property type="development level" value="Tbio"/>
</dbReference>
<dbReference type="PRO" id="PR:P29590"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 15"/>
</dbReference>
<dbReference type="RNAct" id="P29590">
<property type="molecule type" value="protein"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000140464">
<property type="expression patterns" value="Expressed in left lobe of thyroid gland and 216 other tissues"/>
</dbReference>
<dbReference type="ExpressionAtlas" id="P29590">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="P29590">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0000785">
<property type="term" value="C:chromatin"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0005737">
<property type="term" value="C:cytoplasm"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005829">
<property type="term" value="C:cytosol"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0031901">
<property type="term" value="C:early endosome membrane"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0042406">
<property type="term" value="C:extrinsic component of endoplasmic reticulum membrane"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0000792">
<property type="term" value="C:heterochromatin"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0000784">
<property type="term" value="C:nuclear chromosome, telomeric region"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0016363">
<property type="term" value="C:nuclear matrix"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0031965">
<property type="term" value="C:nuclear membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005730">
<property type="term" value="C:nucleolus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005654">
<property type="term" value="C:nucleoplasm"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005634">
<property type="term" value="C:nucleus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0016605">
<property type="term" value="C:PML body"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0050897">
<property type="term" value="F:cobalt ion binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0003677">
<property type="term" value="F:DNA binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0046982">
<property type="term" value="F:protein heterodimerization activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042803">
<property type="term" value="F:protein homodimerization activity"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0046332">
<property type="term" value="F:SMAD binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0032183">
<property type="term" value="F:SUMO binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0140037">
<property type="term" value="F:sumo-dependent protein binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0003713">
<property type="term" value="F:transcription coactivator activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0031625">
<property type="term" value="F:ubiquitin protein ligase binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0004842">
<property type="term" value="F:ubiquitin-protein transferase activity"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0008270">
<property type="term" value="F:zinc ion binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006919">
<property type="term" value="P:activation of cysteine-type endopeptidase activity involved in apoptotic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0006915">
<property type="term" value="P:apoptotic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0060444">
<property type="term" value="P:branching involved in mammary gland duct morphogenesis"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0007050">
<property type="term" value="P:cell cycle arrest"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045165">
<property type="term" value="P:cell fate commitment"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0071353">
<property type="term" value="P:cellular response to interleukin-4"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:1990830">
<property type="term" value="P:cellular response to leukemia inhibitory factor"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0090398">
<property type="term" value="P:cellular senescence"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0032922">
<property type="term" value="P:circadian regulation of gene expression"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0007182">
<property type="term" value="P:common-partner SMAD protein phosphorylation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0051607">
<property type="term" value="P:defense response to virus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0006977">
<property type="term" value="P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0032469">
<property type="term" value="P:endoplasmic reticulum calcium ion homeostasis"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043153">
<property type="term" value="P:entrainment of circadian clock by photoperiod"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0097191">
<property type="term" value="P:extrinsic apoptotic signaling pathway"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0010761">
<property type="term" value="P:fibroblast migration"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0045087">
<property type="term" value="P:innate immune response"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0060333">
<property type="term" value="P:interferon-gamma-mediated signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0008630">
<property type="term" value="P:intrinsic apoptotic signaling pathway in response to DNA damage"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042771">
<property type="term" value="P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0070059">
<property type="term" value="P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0008631">
<property type="term" value="P:intrinsic apoptotic signaling pathway in response to oxidative stress"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0051457">
<property type="term" value="P:maintenance of protein location in nucleus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0030099">
<property type="term" value="P:myeloid cell differentiation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0016525">
<property type="term" value="P:negative regulation of angiogenesis"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0030308">
<property type="term" value="P:negative regulation of cell growth"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008285">
<property type="term" value="P:negative regulation of cell population proliferation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0050713">
<property type="term" value="P:negative regulation of interleukin-1 beta secretion"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0045930">
<property type="term" value="P:negative regulation of mitotic cell cycle"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0051974">
<property type="term" value="P:negative regulation of telomerase activity"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0032211">
<property type="term" value="P:negative regulation of telomere maintenance via telomerase"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045892">
<property type="term" value="P:negative regulation of transcription, DNA-templated"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0032938">
<property type="term" value="P:negative regulation of translation in response to oxidative stress"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:2000059">
<property type="term" value="P:negative regulation of ubiquitin-dependent protein catabolic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1902187">
<property type="term" value="P:negative regulation of viral release from host cell"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0030578">
<property type="term" value="P:PML body organization"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0060058">
<property type="term" value="P:positive regulation of apoptotic process involved in mammary gland involution"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:2001235">
<property type="term" value="P:positive regulation of apoptotic signaling pathway"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0002230">
<property type="term" value="P:positive regulation of defense response to virus by host"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:2001238">
<property type="term" value="P:positive regulation of extrinsic apoptotic signaling pathway"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0048146">
<property type="term" value="P:positive regulation of fibroblast proliferation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0031065">
<property type="term" value="P:positive regulation of histone deacetylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1904816">
<property type="term" value="P:positive regulation of protein localization to chromosome, telomeric region"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0032206">
<property type="term" value="P:positive regulation of telomere maintenance"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045893">
<property type="term" value="P:positive regulation of transcription, DNA-templated"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0043161">
<property type="term" value="P:proteasome-mediated ubiquitin-dependent protein catabolic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006606">
<property type="term" value="P:protein import into nucleus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0050821">
<property type="term" value="P:protein stabilization"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006605">
<property type="term" value="P:protein targeting"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0065003">
<property type="term" value="P:protein-containing complex assembly"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010522">
<property type="term" value="P:regulation of calcium ion transport into cytosol"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0030155">
<property type="term" value="P:regulation of cell adhesion"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0042752">
<property type="term" value="P:regulation of circadian rhythm"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:2000779">
<property type="term" value="P:regulation of double-strand break repair"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001932">
<property type="term" value="P:regulation of protein phosphorylation"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1901796">
<property type="term" value="P:regulation of signal transduction by p53 class mediator"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0006355">
<property type="term" value="P:regulation of transcription, DNA-templated"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0034097">
<property type="term" value="P:response to cytokine"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0010332">
<property type="term" value="P:response to gamma radiation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0001666">
<property type="term" value="P:response to hypoxia"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0009411">
<property type="term" value="P:response to UV"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0048384">
<property type="term" value="P:retinoic acid receptor signaling pathway"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0007179">
<property type="term" value="P:transforming growth factor beta receptor signaling pathway"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0016032">
<property type="term" value="P:viral process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="Gene3D" id="3.30.40.10">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="InterPro" id="IPR021978">
<property type="entry name" value="DUF3583"/>
</dbReference>
<dbReference type="InterPro" id="IPR000315">
<property type="entry name" value="Znf_B-box"/>
</dbReference>
<dbReference type="InterPro" id="IPR001841">
<property type="entry name" value="Znf_RING"/>
</dbReference>
<dbReference type="InterPro" id="IPR013083">
<property type="entry name" value="Znf_RING/FYVE/PHD"/>
</dbReference>
<dbReference type="InterPro" id="IPR017907">
<property type="entry name" value="Znf_RING_CS"/>
</dbReference>
<dbReference type="Pfam" id="PF12126">
<property type="entry name" value="DUF3583"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF00643">
<property type="entry name" value="zf-B_box"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00336">
<property type="entry name" value="BBOX"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00184">
<property type="entry name" value="RING"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50119">
<property type="entry name" value="ZF_BBOX"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="PROSITE" id="PS00518">
<property type="entry name" value="ZF_RING_1"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50089">
<property type="entry name" value="ZF_RING_2"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0007">Acetylation</keyword>
<keyword id="KW-0010">Activator</keyword>
<keyword id="KW-0025">Alternative splicing</keyword>
<keyword id="KW-0051">Antiviral defense</keyword>
<keyword id="KW-0053">Apoptosis</keyword>
<keyword id="KW-0090">Biological rhythms</keyword>
<keyword id="KW-0160">Chromosomal rearrangement</keyword>
<keyword id="KW-0175">Coiled coil</keyword>
<keyword id="KW-0963">Cytoplasm</keyword>
<keyword id="KW-0238">DNA-binding</keyword>
<keyword id="KW-0256">Endoplasmic reticulum</keyword>
<keyword id="KW-0967">Endosome</keyword>
<keyword id="KW-0945">Host-virus interaction</keyword>
<keyword id="KW-0391">Immunity</keyword>
<keyword id="KW-0399">Innate immunity</keyword>
<keyword id="KW-1017">Isopeptide bond</keyword>
<keyword id="KW-0472">Membrane</keyword>
<keyword id="KW-0479">Metal-binding</keyword>
<keyword id="KW-0539">Nucleus</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-0656">Proto-oncogene</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0677">Repeat</keyword>
<keyword id="KW-0804">Transcription</keyword>
<keyword id="KW-0805">Transcription regulation</keyword>
<keyword id="KW-0043">Tumor suppressor</keyword>
<keyword id="KW-0832">Ubl conjugation</keyword>
<keyword id="KW-0862">Zinc</keyword>
<keyword id="KW-0863">Zinc-finger</keyword>
<feature type="chain" description="Protein PML" id="PRO_0000056001">
<location>
<begin position="1"/>
<end position="882"/>
</location>
</feature>
<feature type="zinc finger region" description="RING-type" evidence="20">
<location>
<begin position="57"/>
<end position="92"/>
</location>
</feature>
<feature type="zinc finger region" description="B box-type 1; atypical" evidence="19">
<location>
<begin position="124"/>
<end position="166"/>
</location>
</feature>
<feature type="zinc finger region" description="B box-type 2" evidence="19">
<location>
<begin position="183"/>
<end position="236"/>
</location>
</feature>
<feature type="region of interest" description="Interaction with PER2" evidence="63">
<location>
<begin position="448"/>
<end position="555"/>
</location>
</feature>
<feature type="region of interest" description="Sumo interaction motif (SIM)">
<location>
<begin position="556"/>
<end position="562"/>
</location>
</feature>
<feature type="coiled-coil region" evidence="18">
<location>
<begin position="228"/>
<end position="253"/>
</location>
</feature>
<feature type="short sequence motif" description="Nuclear localization signal">
<location>
<begin position="476"/>
<end position="490"/>
</location>
</feature>
<feature type="compositionally biased region" description="Pro-rich">
<location>
<begin position="3"/>
<end position="46"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Zinc 1">
<location>
<position position="57"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Zinc 1">
<location>
<position position="60"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Zinc 2">
<location>
<position position="72"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Zinc 2">
<location>
<position position="74"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Zinc 1">
<location>
<position position="77"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Zinc 1">
<location>
<position position="80"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Zinc 2">
<location>
<position position="88"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Zinc 2">
<location>
<position position="91"/>
</location>
</feature>
<feature type="site" description="Breakpoint for translocation to form PML-RARA oncogene in type A APL">
<location>
<begin position="394"/>
<end position="395"/>
</location>
</feature>
<feature type="site" description="Breakpoint for translocation to form PML-RARA oncogene in type B APL">
<location>
<begin position="552"/>
<end position="553"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by HIPK2" evidence="11 48">
<location>
<position position="8"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by HIPK2 and MAPK1" evidence="10 11">
<location>
<position position="36"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by HIPK2 and MAPK1" evidence="10 48">
<location>
<position position="38"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="10">
<location>
<position position="48"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by CHEK2" evidence="29">
<location>
<position position="117"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by MAPK1 and MAPK7" evidence="5 6 10 11 60">
<location>
<position position="403"/>
</location>
</feature>
<feature type="modified residue" description="N6-acetyllysine; alternate" evidence="47 63">
<location>
<position position="487"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="17">
<location>
<position position="493"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="17">
<location>
<position position="504"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by MAPK1" evidence="10 60">
<location>
<position position="505"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="10">
<location>
<position position="512"/>
</location>
</feature>
<feature type="modified residue" description="N6-acetyllysine" evidence="91">
<location>
<position position="515"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by CDK1 and CDK2" evidence="5 6 8 9 10 11 57 60">
<location>
<position position="518"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by MAPK1" evidence="5 6 8 9 10 11 60">
<location>
<position position="527"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by MAPK1" evidence="5 6 7 9 10 11">
<location>
<position position="530"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by CK2" evidence="64">
<location>
<position position="565"/>
</location>
</feature>
<feature type="modified residue" description="Phosphothreonine" evidence="10">
<location>
<position position="867"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate" evidence="24">
<location>
<position position="65"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate" evidence="12 13 14 15">
<location>
<position position="65"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate" evidence="24">
<location>
<position position="160"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1P1/SUMO5); alternate" evidence="76">
<location>
<position position="160"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate" evidence="13 14 15">
<location>
<position position="160"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in /SUMO5); alternate" evidence="76">
<location>
<position position="380"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate" evidence="12 13 15">
<location>
<position position="380"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate" evidence="46">
<location>
<position position="380"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)" evidence="13 15">
<location>
<position position="394"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1P1/SUMO5); alternate" evidence="76">
<location>
<position position="400"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate" evidence="46">
<location>
<position position="400"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate" evidence="15">
<location>
<position position="401"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate" evidence="46">
<location>
<position position="401"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)" evidence="15">
<location>
<position position="460"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate" evidence="15">
<location>
<position position="476"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate" evidence="46">
<location>
<position position="476"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)" evidence="13 15">
<location>
<position position="478"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate" evidence="15">
<location>
<position position="487"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate" evidence="24">
<location>
<position position="490"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1P1/SUMO5); alternate" evidence="76">
<location>
<position position="490"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate" evidence="12 13 14 15">
<location>
<position position="490"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate">
<location>
<position position="497"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1P1/SUMO5); alternate" evidence="76">
<location>
<position position="497"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate" evidence="15">
<location>
<position position="497"/>
</location>
</feature>
<feature type="splice variant" description="In isoform PML-11, isoform PML-12 and isoform PML-13." id="VSP_040590" evidence="81 83 88 89">
<location>
<begin position="419"/>
<end position="466"/>
</location>
</feature>
<feature type="splice variant" description="In isoform PML-7." id="VSP_040591" evidence="81">
<original>PEEAERVKAQVQALGLA</original>
<variation>LPPPAHALTGPAQSSTH</variation>
<location>
<begin position="419"/>
<end position="435"/>
</location>
</feature>
<feature type="splice variant" description="In isoform PML-14." id="VSP_040592" evidence="81">
<original>PEEAE</original>
<variation>RNALW</variation>
<location>
<begin position="419"/>
<end position="423"/>
</location>
</feature>
<feature type="splice variant" description="In isoform PML-14." id="VSP_040593" evidence="81">
<location>
<begin position="424"/>
<end position="882"/>
</location>
</feature>
<feature type="splice variant" description="In isoform PML-7." id="VSP_040594" evidence="81">
<location>
<begin position="436"/>
<end position="882"/>
</location>
</feature>
<feature type="splice variant" description="In isoform PML-6." id="VSP_005742" evidence="81 84 87">
<original>EERVVVIS</original>
<variation>GRERNALW</variation>
<location>
<begin position="553"/>
<end position="560"/>
</location>
</feature>
<feature type="splice variant" description="In isoform PML-6." id="VSP_005743" evidence="81 84 87">
<location>
<begin position="561"/>
<end position="882"/>
</location>
</feature>
<feature type="splice variant" description="In isoform PML-2 and isoform PML-13." id="VSP_040595" evidence="81 83 88">
<original>SSRELDDSSSESSDLQLEGPSTLRVLDENLADPQAEDRPLVFFDLKIDNETQKISQLAAVNRESKFRVVIQPEAFFSIYSKAVSLEVGLQHFLSFLSSMRRPILACYKLWGPGLPNFFRALEDINRLWEFQEAISGFLAALPLIRERVPGASSFKLKNLAQTYLARNMSERSAMAAVLAMRDLCRLLEVSPGPQLAQHVYPFSSLQCFASLQPLVQAAVLPRAEARLLALHNVSFMELLSAHRRDRQGGLKKYSRYLSLQTTTLPPAQPAFNLQALGTYFEGLLEGPALARAEGVSTPLAGRGLAERASQQS</original>
<variation>CMEPMETAEPQSSPAHSSPAHSSPAHSSPVQSLLRAQGASSLPCGTYHPPAWPPHQPAEQAATPDAEPHSEPPDHQERPAVHRGIRYLLYRAQRAIRLRHALRLHPQLHRAPIRTWSPHVVQASTPAITGPLNHPANAQEHPAQLQRGISPPHRIRGAVRSRSRSLRGSSHLSQWLNNFFALPFSSMASQLDMSSVVGAGESRAQTLGAGVPPGDSVRGSMEASQVQVPLEASPITFPPPCAPERPPISPVPGARQAGL</variation>
<location>
<begin position="571"/>
<end position="882"/>
</location>
</feature>
<feature type="splice variant" description="In isoform PML-8." id="VSP_005741" evidence="81 86">
<original>SSRELDDSSSESSDLQLEGPSTLRVLDENLADPQAEDRPLVFFDLKIDNETQKISQLAAVNRESKFRVVIQPEAFFSIYSKAVSLEVGLQHFLSFLSSMRRPILACYKLWGPGLPNFFRALEDINRLWEFQEAISGFLAALPLIRERVPGASSFKLKNLAQTYLARNMSERSAMAAVLAMRDLCRLLEVSPGPQLAQHVYPFSSLQCFASLQPLVQAAVLPRAEARLLALHNVSFMELLSAHRRDRQGGLKKYSRYLSLQTTTLPPAQPAFNLQALGTYFEGLLEGPALARAEGVSTPLAGRGLAERASQQS</original>
<variation>CMEPMETAEPQSSPAHSSPAHSSPVQSLLRAQGASSLPCGTYHPPAWPPHQPAEQAATPDAEPHSEPPDHQERPAVHRGIRYLLYRAQRAIRLRHALRLHPQLHRAPIRTWSPHVVQASTPAITGPLNHPANAQEHPAQLQRGISPPHRIRGAVRSRSRSLRGSSHLSQWLNNFFALPFSSMASQLDMSSVVGAGESRAQTLGAGVPPGDSVRGSMEASQVQVPLEASPITFPPPCAPERPPISPVPGARQAGL</variation>
<location>
<begin position="571"/>
<end position="882"/>
</location>
</feature>
<feature type="splice variant" description="In isoform PML-3." id="VSP_040596" evidence="85">
<original>SSRELDDSSSESSDLQLEGPSTLRVLDENLADPQAEDRPLVFFDLKIDNETQKISQLAAVNRESKFRVVIQ</original>
<variation>VSSSPQSEVLYWKVHGAHGDRRATVLASPLLASPLLASPLLASPVSAESTRSLQPALWHIPPPSLASPPAR</variation>
<location>
<begin position="571"/>
<end position="641"/>
</location>
</feature>
<feature type="splice variant" description="In isoform PML-5." id="VSP_005739" evidence="81 86">
<original>SSRELDDSSSESSDLQLEGPSTLRVLDENLADPQAEDRPLV</original>
<variation>VSGPEVQPRTPASPHFRSQGAQPQQVTLRLALRLGNFPVRH</variation>
<location>
<begin position="571"/>
<end position="611"/>
</location>
</feature>
<feature type="splice variant" description="In isoform PML-5." id="VSP_005740" evidence="81 86">
<location>
<begin position="612"/>
<end position="882"/>
</location>
</feature>
<feature type="splice variant" description="In isoform PML-4 and isoform PML-12." id="VSP_005744" evidence="81 82">
<original>TQKISQLAAVNRE</original>
<variation>SGFSWGYPHPFLI</variation>
<location>
<begin position="621"/>
<end position="633"/>
</location>
</feature>
<feature type="splice variant" description="In isoform PML-4 and isoform PML-12." id="VSP_005745" evidence="81 82">
<location>
<begin position="634"/>
<end position="882"/>
</location>
</feature>
<feature type="splice variant" description="In isoform PML-3." id="VSP_040597" evidence="85">
<location>
<begin position="642"/>
<end position="882"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs5742915." id="VAR_052090" evidence="26 44">
<original>F</original>
<variation>L</variation>
<location>
<position position="645"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced sumoylation; when associated with S-60." evidence="42">
<original>C</original>
<variation>S</variation>
<location>
<position position="57"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced sumoylation; when associated with S-57." evidence="42">
<original>C</original>
<variation>S</variation>
<location>
<position position="60"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of one sumoylation. No effect on nuclear body formation. Loss of 2 sumoylations; when associated with R-490 with or without R-133 or R-150. No effect on nuclear body formation; when associated with R-490. Loss the ability to be conjugated by SUMO1P1/SUMO5 but could be conjugated by SUMO1; when associated with R-160 and R-490." evidence="76 80">
<original>K</original>
<variation>R</variation>
<location>
<position position="65"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of one sumoylation. No effect on nuclear body formation. Loss of 2 sumoylations; when associated with R-490 with or without R-133 or R-150. No effect on nuclear body formation; when associated with R-490. No sumoylation nor nuclear body formation; when associated with R-160 and R-490." evidence="80">
<original>K</original>
<variation>R</variation>
<location>
<position position="65"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on sumoylation levels.">
<original>K</original>
<variation>R</variation>
<location>
<position position="68"/>
</location>
</feature>
<feature type="mutagenesis site" description="No nuclear microspeckle location, no sumoylation and loss of intrinsic transcriptional repressor activity of PML-RARA oncoprotein; when associated with R-89." evidence="40">
<original>C</original>
<variation>S</variation>
<location>
<position position="88"/>
</location>
</feature>
<feature type="mutagenesis site" description="No nuclear microspeckle location, no sumoylation and loss of intrinsic transcriptional repressor activity of PML-RARA oncoprotein; when associated with S-88." evidence="40">
<original>P</original>
<variation>R</variation>
<location>
<position position="89"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of 2 sumoylations; when associated with R-65 and R-490." evidence="80">
<original>K</original>
<variation>R</variation>
<location>
<position position="133"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of 2 sumoylations; when associated with R-65 and R-490." evidence="80">
<original>K</original>
<variation>R</variation>
<location>
<position position="150"/>
</location>
</feature>
<feature type="mutagenesis site" description="Compromised the formation of high molecular weight species of SUMO1P1/SUMO5 conjugation on PML. Loss of 2 sumoylations; when associated with or without R-65. No sumoylation nor nuclear body formation; when associated with or without R-65 and R-490. Loss the ability to be conjugated by SUMO1P1/SUMO5 but could be conjugated by SUMO1; when associated with R-65 and R-490." evidence="76 80">
<original>K</original>
<variation>R</variation>
<location>
<position position="160"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of 2 sumoylations; when associated with or without R-65. No sumoylation nor nuclear body formation; when associated with or without R-65 and R-490." evidence="80">
<original>K</original>
<variation>R</variation>
<location>
<position position="160"/>
</location>
</feature>
<feature type="mutagenesis site" description="Does not affect SUMO1P1/SUMO5 conjugation." evidence="76">
<original>K</original>
<variation>R</variation>
<location>
<position position="380"/>
</location>
</feature>
<feature type="mutagenesis site" description="Does not affect SUMO1P1/SUMO5 conjugation." evidence="76">
<original>K</original>
<variation>R</variation>
<location>
<position position="400"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of nuclear localization; when associated with A-490." evidence="45 47">
<original>K</original>
<variation>A</variation>
<location>
<position position="487"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of nuclear localization. Reduced acetylation. Further decrease in acetylation; when associated with R-515." evidence="45 47">
<original>K</original>
<variation>R</variation>
<location>
<position position="487"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of nuclear localization; when associated with A-487." evidence="45 80">
<original>K</original>
<variation>A</variation>
<location>
<position position="490"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolished conjugation of one SUMO1P1/SUMO5. Loss of 2 sumoylations; when associated with R-65 with or without R-133. No effect on nuclear body formation; when associated with R-65. No sumoylation nor nuclear body formation; when associated with R-65 and R-160. Loss the ability to be conjugated by SUMO1P1/SUMO5 but could be conjugated by SUMO1; when associated with R-65 and R-160." evidence="45 76 80">
<original>K</original>
<variation>R</variation>
<location>
<position position="490"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of 2 sumoylations; when associated with R-65 with or without R-133. No effect on nuclear body formation; when associated with R-65. No sumoylation nor nuclear body formation; when associated with R-65 and R-160." evidence="45 80">
<original>K</original>
<variation>R</variation>
<location>
<position position="490"/>
</location>
</feature>
<feature type="mutagenesis site" description="Does not affect SUMO1P1/SUMO5 conjugation." evidence="76">
<original>K</original>
<variation>R</variation>
<location>
<position position="497"/>
</location>
</feature>
<feature type="mutagenesis site" description="Slightly reduced acetylation. Further decrease in acetylation; when associated with R-487." evidence="47">
<original>K</original>
<variation>R</variation>
<location>
<position position="515"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes ubiquitination by the BCR(KLHL20) E3 ubiquitin ligase complex." evidence="57">
<original>S</original>
<variation>A</variation>
<location>
<position position="518"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes SUMO1 binding.">
<original>VVVI</original>
<variation>AAAS</variation>
<location>
<begin position="556"/>
<end position="559"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 7; AAP88913 and 10; AAH00080/AAH20994." ref="7 10" evidence="90">
<original>E</original>
<variation>D</variation>
<location>
<position position="224"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 2; AAA60351/AAA60388/AAA60390, 4; AAA60352 and 5; AAG50182/AAG50184/AAG50185." ref="2 4 5" evidence="90">
<original>P</original>
<variation>A</variation>
<location>
<position position="419"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="54"/>
<end position="56"/>
</location>
</feature>
<feature type="turn" evidence="2">
<location>
<begin position="58"/>
<end position="60"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="62"/>
<end position="66"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="78"/>
<end position="82"/>
</location>
</feature>
<feature type="turn" evidence="2">
<location>
<begin position="89"/>
<end position="91"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="93"/>
<end position="96"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="121"/>
<end position="126"/>
</location>
</feature>
<feature type="turn" evidence="3">
<location>
<begin position="130"/>
<end position="132"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="138"/>
<end position="140"/>
</location>
</feature>
<feature type="turn" evidence="3">
<location>
<begin position="141"/>
<end position="144"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="145"/>
<end position="147"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="149"/>
<end position="158"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="163"/>
<end position="165"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="556"/>
<end position="558"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="5">
<location sequence="P29590-2">
<position position="565"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 5; AAG50181." ref="5" evidence="90">
<original>P</original>
<variation>A</variation>
<location sequence="P29590-2">
<position position="578"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="5">
<location sequence="P29590-4">
<position position="518"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="5">
<location sequence="P29590-4">
<position position="527"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="5">
<location sequence="P29590-4">
<position position="530"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 5; AAG50187." ref="5" evidence="90">
<original>L</original>
<variation>V</variation>
<location sequence="P29590-10">
<position position="419"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1BOR"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5YUF"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="6IMQ"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PDB" id="6UYR"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="17081983"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="18669648"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="19690332"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="20068231"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="21406692"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="23186163"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="24275569"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="25218447"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="25755297"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="25772364"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="28112733"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000250"/>
<evidence key="17" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="Q60953"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000255"/>
<evidence key="19" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00024"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00175"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10610177"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10669754"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10684855"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10779416"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11025664"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11331580"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11432836"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12006491"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12402044"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12419228"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12439746"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12773567"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12810724"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14645235"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14976184"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15136035"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15195100"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15356634"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15467728"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15809060"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1652369"/>
</source>
</evidence>
<evidence key="42" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17081985"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17173041"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1720570"/>
</source>
</evidence>
<evidence key="45" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18298799"/>
</source>
</evidence>
<evidence key="46" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18408734"/>
</source>
</evidence>
<evidence key="47" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18621739"/>
</source>
</evidence>
<evidence key="48" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19015637"/>
</source>
</evidence>
<evidence key="49" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19567472"/>
</source>
</evidence>
<evidence key="50" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20378816"/>
</source>
</evidence>
<evidence key="51" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20501696"/>
</source>
</evidence>
<evidence key="52" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20625391"/>
</source>
</evidence>
<evidence key="53" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20639899"/>
</source>
</evidence>
<evidence key="54" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21148299"/>
</source>
</evidence>
<evidence key="55" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21304940"/>
</source>
</evidence>
<evidence key="56" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21639834"/>
</source>
</evidence>
<evidence key="57" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21840486"/>
</source>
</evidence>
<evidence key="58" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21994459"/>
</source>
</evidence>
<evidence key="59" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22002537"/>
</source>
</evidence>
<evidence key="60" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22033920"/>
</source>
</evidence>
<evidence key="61" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22117195"/>
</source>
</evidence>
<evidence key="62" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22155184"/>
</source>
</evidence>
<evidence key="63" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22274616"/>
</source>
</evidence>
<evidence key="64" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22406621"/>
</source>
</evidence>
<evidence key="65" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22629402"/>
</source>
</evidence>
<evidence key="66" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22685230"/>
</source>
</evidence>
<evidence key="67" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22773875"/>
</source>
</evidence>
<evidence key="68" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22869143"/>
</source>
</evidence>
<evidence key="69" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22875967"/>
</source>
</evidence>
<evidence key="70" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23007646"/>
</source>
</evidence>
<evidence key="71" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23028697"/>
</source>
</evidence>
<evidence key="72" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23135708"/>
</source>
</evidence>
<evidence key="73" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23430110"/>
</source>
</evidence>
<evidence key="74" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23431171"/>
</source>
</evidence>
<evidence key="75" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="25772236"/>
</source>
</evidence>
<evidence key="76" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="27211601"/>
</source>
</evidence>
<evidence key="77" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="28842558"/>
</source>
</evidence>
<evidence key="78" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9420283"/>
</source>
</evidence>
<evidence key="79" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9570750"/>
</source>
</evidence>
<evidence key="80" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9756909"/>
</source>
</evidence>
<evidence key="81" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="11331580"/>
</source>
</evidence>
<evidence key="82" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="1311253"/>
</source>
</evidence>
<evidence key="83" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="15489334"/>
</source>
</evidence>
<evidence key="84" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="1652368"/>
</source>
</evidence>
<evidence key="85" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="1652369"/>
</source>
</evidence>
<evidence key="86" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="1720570"/>
</source>
</evidence>
<evidence key="87" type="ECO:0000303">
<source ref="6"/>
</evidence>
<evidence key="88" type="ECO:0000303">
<source ref="7"/>
</evidence>
<evidence key="89" type="ECO:0000303">
<source ref="8"/>
</evidence>
<evidence key="90" type="ECO:0000305"/>
<evidence key="91" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="18621739"/>
</source>
</evidence>
<sequence length="882" mass="97551" checksum="D50968A977E34287" modified="2008-11-25" version="3">MEPAPARSPRPQQDPARPQEPTMPPPETPSEGRQPSPSPSPTERAPASEEEFQFLRCQQCQAEAKCPKLLPCLHTLCSGCLEASGMQCPICQAPWPLGADTPALDNVFFESLQRRLSVYRQIVDAQAVCTRCKESADFWCFECEQLLCAKCFEAHQWFLKHEARPLAELRNQSVREFLDGTRKTNNIFCSNPNHRTPTLTSIYCRGCSKPLCCSCALLDSSHSELKCDISAEIQQRQEELDAMTQALQEQDSAFGAVHAQMHAAVGQLGRARAETEELIRERVRQVVAHVRAQERELLEAVDARYQRDYEEMASRLGRLDAVLQRIRTGSALVQRMKCYASDQEVLDMHGFLRQALCRLRQEEPQSLQAAVRTDGFDEFKVRLQDLSSCITQGKDAAVSKKASPEAASTPRDPIDVDLPEEAERVKAQVQALGLAEAQPMAVVQSVPGAHPVPVYAFSIKGPSYGEDVSNTTTAQKRKCSQTQCPRKVIKMESEEGKEARLARSSPEQPRPSTSKAVSPPHLDGPPSPRSPVIGSEVFLPNSNHVASGAGEAEERVVVISSSEDSDAENSSSRELDDSSSESSDLQLEGPSTLRVLDENLADPQAEDRPLVFFDLKIDNETQKISQLAAVNRESKFRVVIQPEAFFSIYSKAVSLEVGLQHFLSFLSSMRRPILACYKLWGPGLPNFFRALEDINRLWEFQEAISGFLAALPLIRERVPGASSFKLKNLAQTYLARNMSERSAMAAVLAMRDLCRLLEVSPGPQLAQHVYPFSSLQCFASLQPLVQAAVLPRAEARLLALHNVSFMELLSAHRRDRQGGLKKYSRYLSLQTTTLPPAQPAFNLQALGTYFEGLLEGPALARAEGVSTPLAGRGLAERASQQS</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution (CC BY 4.0) License
</copyright>
</uniprot>
